Wednesday, 07. June 2023

Opening Plenary
18:30 - 20:00 R6

Opening Plenary

The future of CF care 18:30 - 18:50
Speaker: Nicholas Simmonds, GB

Thursday, 08. June 2023

Meet the Experts
07:30 - 08:20

***MTE03* - Meet the Experts 03 - Management of haemoptysis in cystic fibrosis**

Chair: Andrew Jones, GB
Chair: Malena Cohen-Cymberknoh, IL

Meet the Experts
07:30 - 08:20

Meet the Experts

Meet the Experts
07:30 - 08:20

***MTE02* - Meet the Experts 02 - Diagnosis and management of CFTR-RD**

Chair: Carlo Castellani, IT
Chair: Nicholas Simmonds, GB

Meet the Experts
07:30 - 08:20

***MTE01* - Meet the Experts 01 - What's new in CF-related biofilm research?**

Chair: Tom Coenye, BE
Chair: Susanne Haussler, DE

Symposium
08:30 - 10:00 R1

***S01* - Symposium 01 - Closing the gap: treating all patients with gene-protein therapies**

Chair: Kors Van der Ent, NL
Chair: Margarida Amaral, PT

Gene therapy in cystic fibrosis: the holy grail? 08:30 - 08:52
Speaker: Eric Alton, GB

Rare mutations and modulators: who's left to treat? 08:52 - 09:14
Speaker: Jeffrey Beekman, NL

CFTR modulator non-responders: pharmacogenetics and complex alleles 09:14 - 09:36
Speaker: Nicoletta Pedemonte, IT

Treating nonsense mutations: what's left to do? 09:36 - 10:00
Speaker: Fabrice Lejeune, FR

Symposium
08:30 - 10:00 R2

***S02* - Symposium 02 - Antibiotic therapy in cystic fibrosis – state of the art**

Chair: Jean-Luc Mainardi, FR
Chair: Annamaria Bevivino, IT

Interspecies interactions and their effect on antibiotic efficacy 08:30 - 08:52
Speaker: Michael Bottery, GB

Tolerance of *Pseudomonas aeruginosa* biofilms – why it 08:52 - 09:14

matters
Speaker: Susanne Haussler, DE

Antimicrobial susceptibility testing in cystic fibrosis: is it still relevant? 09:14 - 09:36
Speaker: Valerie Waters, CA

New hits and validated drug targets in the fight against Mycobacterium abscessus and other nontuberculous mycobacteria 09:36 - 10:00
Speaker: Laurent Kremer, FR

Symposium
08:30 - 10:00 R3

***S03* - Symposium 03 - Harmonising global care in cystic fibrosis**

Chair: Silvia Gartner, ES
Chair: Ernst Eber, AT

ECFS Twinning Project – goals, progress and challenges 08:30 - 08:52
Speaker: Pavel Drevinek, CZ

Challenges for cystic fibrosis care in developing countries 08:52 - 09:14
Speaker: Marco Zampoli, ZA

How to overcome challenges with drug access and reimbursement 09:14 - 09:36
Speaker: Kris De Boeck, BE

Novel programmes for enhancing drug access 09:36 - 10:00
Speaker: Clémence Martin, FR

Symposium
08:30 - 10:00 R4

***S04* - Symposium 04 - The times are changing and we are changing with them**

Chair: Trudy Havermans, BE
Chair: Pavla Hodkova, CZ

Change in illness perception and identity – what do we know today? 08:30 - 08:52
Speaker: Horst Mitmansgruber, AT

Mental health and quality of life - new measures in evaluation, research and screening? 08:52 - 09:14
Speaker: Sonia Graziano, IT

Patient education - what do patients need to know and what skills should they be taught? 09:14 - 09:36
Speaker: Helen Chadwick, GB

Collaboration – the science of shared decision making in the light of upheaval and uncertainty 09:36 - 10:00
Speaker: Johanna Gardecki, DE

Symposium
08:30 - 10:00 R5

***S05* - Symposium 05 - Controversies in the world of screening for cystic fibrosis**

Chair: Jürg Barben, CH
Chair: Kevin Southern, GB

Prenatal screening for cystic fibrosis remains justified in the era of CFTR modulator therapy: PRO 08:30 - 08:48
Speaker: Hannah Blau, IL

Prenatal screening for cystic fibrosis remains justified in the era of CFTR modulator therapy: CON 08:48 - 09:06
Speaker: John Massie, AU

Discussion 09:06 - 09:16

How to make newborn screening for cystic fibrosis ethnically fairer 09:16 - 09:38
Speaker: Maya Desai, GB

Is it time to revisit the ECFS standards to reduce false positive results in newborn screening? 09:38 - 10:00
Speaker: Olaf Sommerburg, DE

Industry Sessions
10:00 - 10:30

CF Innovation Zone - Exhibitor Presentations

Chair: Damian Downey, GB

Symposium
10:30 - 12:00 R1

***S06* - Symposium 06 - Pulmonary challenges post access to CFTR modulators**

Chair: Jane Davies, GB
Chair: Isabelle Durieu, FR

Strategies for infection control and surveillance in non-productive patients 10:30 - 10:52
Speaker: Claire Wainwright, AU

Diagnosis and management of pulmonary exacerbations in CFTR modulator responsive patients 10:52 - 11:14
Speaker: Barry Plant, IE

How to monitor people with preserved lung function at all ages? 11:14 - 11:36
Speaker: Mirjam Stahl, DE

How do we make remote monitoring work in cystic fibrosis? 11:36 - 12:00
Speaker: Nicholas Simmonds, GB

Symposium
10:30 - 12:00 R2

***S07* - Symposium 07 - Microbiology in the era of CFTR modulators**

Chair: Deborah Baines, GB
Chair: Tom Coenye, BE

Effects of CFTR modulators on inflammation in cystic fibrosis 10:30 - 10:52

Speaker: Michal Shteinberg, IL

Impact of airway inflammation and infection on the efficacy of CFTR modulators 10:52 - 11:14
Speaker: Carla Ribeiro, US

The effect of CFTR modulators on airway bacteriology in cystic fibrosis patients 11:14 - 11:36
Speaker: Helle Krogh Johansen, DK

Impact of CFTR modulators on IV antibiotic use 11:36 - 12:00
Speaker: Ruth Keogh, GB

Symposium
10:30 - 12:00 R3

***S08* - Symposium 08 - Gene based-therapeutic approaches: novel delivery systems and beyond**

Chair: Anna Cereseto, IT
Chair: Patrick Harrison, IE

Advances in liposome and polymer systems for cystic fibrosis gene therapy 10:30 - 10:52
Speaker: Stephen Hart, GB

Advances in AAV platforms for efficient gene therapy 10:52 - 11:14
Speaker: Hildegard Büning, DE

Inhalable RNA formulations based on lung surfactant and repurposed cationic amphiphilic drugs 11:14 - 11:36
Speaker: Koen Raemdonck, BE

Airway stem cell-based therapies for cystic fibrosis sinus disease 11:36 - 12:00
Speaker: Shafagh Waters, AU

Symposium
10:30 - 12:00 R4

***S09* - Symposium 09 - Overweight and healthy lifestyle in cystic fibrosis**

Chair: Chris Smith, GB
Chair: Michael Wilschanski, IL

Dietary approach to treating overweight and obesity in people with cystic fibrosis 10:30 - 10:52
Speaker: Daina Kalnins, CA

Metabolic complications in cystic fibrosis with the preventive nutrition strategy 10:52 - 11:14
Speaker: Andrea Gramegna, IT

CFTR modulators and their impact on body composition – dietitian role 11:14 - 11:36
Speaker: Dimitri Declercq, BE

Evaluating and implementing mindful eating practices in cystic fibrosis – Challenges and opportunities 11:36 - 12:00
Speaker: Helen Egan, GB

Symposium
10:30 - 12:00 R5

***S10* - Symposium 10 - "Things you wish you knew" – hot topics in physiotherapy**

Chair: Gemma Stanford, GB
Chair: Marlies Wagner, AT

Musculoskeletal issues in the modern cystic fibrosis era 10:30 - 10:52
Speaker: Julia Taylor, GB

Cough, spit, suck? - pros, cons and indications for microbiological sputum sampling techniques 10:52 - 11:14
Speaker: Carwyn Bridges, GB

Doing a lot with a little (how to do physiotherapy with limited resources/time/access to medications) 11:14 - 11:36
Speaker: Brenda Morrow, ZA

Fatter but fitter? - exercise requirements for the post-modulator cystic fibrosis population 11:36 - 12:00
Speaker: Wolfgang Gruber, DE

Industry Sessions
12:30 - 14:00 R1

Satellite Symposium

ECFS Tomorrow Lounge Session
12:45 - 13:45 Tomorrow Lounge

Mental Health challenges in the era of new modulators

Speaker: Anna M. Georgiopoulos, US
Speaker: Annette Katscher-Peitz, DE
Speaker: Edwina Landau, IL
Speaker: Alexandra Quittner, US

ePoster Session
14:00 - 15:00 R2

ePoster Session 1

ePoster Session
14:00 - 15:00 R2

***EPS01* - ePoster Session 1: Triple I in cystic fibrosis: Imaging, Inflammation and Immunology**

Chair: Andrea Lakatos-Krepcik, AT
Chair: Tim Lee, GB

EPS1.01 **Using lateral decubitus computed tomography (CT) to monitor structural lung disease in young children with cystic fibrosis** 14:00 - 14:00
Oral Presenter: Rikke Mulvad Sandvik, DK

EPS1.02 **Reanalysis of N_2-lung clearance index and the comparison to SF_6-lung clearance index and magnetic resonance imaging** 14:00 - 14:00
Oral Presenter: Eva Steinke, DE

EPS1.03 **Establishing the utility of oxygen-enhanced (OE-)MRI as a structural and functional measure of cystic fibrosis lung disease: relationships with physiological and cystic fibrosis outcomes** 14:00 - 14:00

Oral Presenter: Christopher Short, GB

EPS1.04	**Change in lung clearance index in adolescents with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor: results from 12 months follow-up in the Danish cystic fibrosis cohort** *Oral Presenter*: Esben Herborg Henriksen, DK	14:00 - 14:00
EPS1.05	**Bronchoscopic practices in adult cystic fibrosis at Cork University Hospital 2012-2022: increased usage, new indications and the emergence of single-use flexible bronchoscopy** *Oral Presenter*: Kevin Deasy, IE	14:00 - 14:00
EPS1.06	**Galectin-3: potential biomarkers in children with cystic fibrosis** *Oral Presenter*: Ismail Guzelkas, TR	14:00 - 14:00
EPS1.07	**Impact of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on *Aspergillus Fumigatus* serology in adults with cystic fibrosis** *Oral Presenter*: Fraser Maxwell Curran, GB	14:00 - 14:00
EPS1.08	**Immunogenic adverse events to CFTR modulators – an international survey** *Oral Presenter*: Ruth M. Urbantat, DE	14:00 - 14:00
EPS1.09	**Feasibility of cardiac magnetic resonance imaging in older cystic fibrosis patients** *Oral Presenter*: Karuna Sapru, GB	14:00 - 14:00
EPS1.10	**Prevalence, risk factors and outcomes of cardiovascular disease in cystic fibrosis: retrospective cohort study in two large patient data registries** *Oral Presenter*: Freddy Frost, GB	14:00 - 14:00

ePoster Session
14:00 - 15:00

ePoster Sessions 2 - 4

ePoster Session
14:00 - 15:00

***EPS03* - ePoster Session 3 - CFTR: what is still puzzling us?**

Chair: Simon Graeber, DE
Chair: Anabela Santo Ramalho, BE

EPS3.02	**The cystic fibrosis urine test: A comprehensive analysis of all renal acid-base parameters following acute oral bicarbonate loading** *Oral Presenter*: Amalie Quist Rousing, DK	14:00 - 14:00
EPS3.04	**Rescuing rare CFTR mutants by a mimetic peptide targeting the AKAP function of PI3Kγ** *Oral Presenter*: Angela Della Sala, IT	14:00 - 14:00
EPS3.05	**Proximity Profiling of CFTR with Gating Mutations** *Oral Presenter*: Melissa Iazzi, CA	14:00 - 14:00
EPS3.07	**Mapping ivacaftor-induced structural changes in CFTR with computer simulations**	14:00 - 14:00

Oral Presenter: David Sheppard, GB

EPS3.08	**Heightened mitochondrial respiration and succinate levels in cystic fibrosis cells is normalised with triple CFTR modulator therapy through mechanisms involving cell calcium flux** *Oral Presenter*: Heledd Jarosz-Griffiths, GB	14:00 - 14:00
EPS3.09	**Transcriptomic and Functional Analysis of Chloride, Bicarbonate, and Proton Secretion Along the Crypt-Villus Axis in Human Intestine: lessons for cystic fibrosis** *Oral Presenter*: Zachary Sellers, US	14:00 - 14:00
EPS3.10	**Novel CFTR modulator combinations directly address the ΔF508-CFTR NBD1 stability defect and enable full CFTR correction** *Oral Presenter*: Gregory Hurlbut, US	14:00 - 14:00

ePoster Session
14:00 - 15:00

***EPS02* - ePoster Session 2 - Empower your patients: how to improve care right from the start**

Chair: Majda Oštir, SI
Chair: Sue Braun, BE

EPS2.01	**Hear my voice: research *by* and *with* children with cystic fibrosis** *Oral Presenter*: Simona Caldani, FR	14:00 - 14:00
EPS2.02	**"You're the person who the decisions are going to be placed on": children with cystic fibrosis and their participation in medical care** *Oral Presenter*: Eleanor Lee Mindel, GB	14:00 - 14:00
EPS2.03	**How can we achieve self-efficacy instead of helplessness caused by frequent medical interventions in young people with cystic fibrosis?** *Oral Presenter*: Karoline Prinz, AT	14:00 - 14:00
EPS2.04	**Expanding the cystic fibrosis mental health screening guidelines: using the pediatric symptom checklist to identify and treat mental health symptoms in children 4-11 years of age** *Oral Presenter*: Emily Muther, US	14:00 - 14:00
EPS2.05	**The challenge of living with cystic fibrosis - short form - challenges experienced by parents/caregivers of children with Cystic Fibrosis in Ireland: the Irish Comparative Outcomes study (ICOS)** *Oral Presenter*: Rini Bhatnagar, IE	14:00 - 14:00
EPS2.06	**What have we been missing all these years? Empowering the patient's voice** *Oral Presenter*: Laura Bundy, GB	14:00 - 14:00
EPS2.07	**The Brief Resilience Scale (BRS) as a possible routine assessment instrument for patients with cystic fibrosis: predictive power in psychological symptoms and quality of life** *Oral Presenter*: Horst Mitmansgruber, AT	14:00 - 14:00

EPS2.08	**Clinical effort against smoke exposure in cystic fibrosis (CEASE-CF): feasibility, acceptability, and preliminary efficacy** *Oral Presenter*: Gabriela Oates, US	14:00 - 14:00
EPS2.09	**Cervical cancer in cystic fibrosis: from treatment to prevention** *Oral Presenter*: Aleksandra Duffy, GB	14:00 - 14:00
EPS2.10	**Initial validation of the Integrated Palliative Care Outcome Scale (IPOS) in adults with cystic fibrosis (CF): data from the *Improving Life with CF* multicentre pragmatic implementation trial** *Oral Presenter*: Anna M. Georgiopoulos, US	14:00 - 14:00

ePoster Session
14:00 - 15:00

***EPS04* - ePoster Session 4 - What's new in CF-related diabetes?**

Chair: Stephanie Van Biervliet, BE
Chair: Frank Bodewes, NL

EPS4.01	**Using a modified glucose challenge test (GCT) as a screening tool for cystic fibrosis diabetes** *Oral Presenter*: Katie Dick, GB	14:00 - 14:00
EPS4.02	**Earlier identification of cystic fibrosis diabetes in children with cystic fibrosis – real-world experience on the use of continuous (flash) glucose monitoring** *Oral Presenter*: Maya Chelminska, GB	14:00 - 14:00
EPS4.03	**An audit of diagnosing cystic fibrosis-related diabetes using newly developed diagnostic criteria using flash glucose monitoring system (Freestyle Libreâ) at a regional adult cystic fibrosis centre** *Oral Presenter*: Claire Roden, GB	14:00 - 14:00
EPS4.04	**A stitch in time saves nine – abnormal glucose tolerance in patients with cystic fibrosis: systematic review and meta-analysis** *Oral Presenter*: Adrienn F. Kéri, HU	14:00 - 14:00
EPS4.05	**Exploring the practicalities and effectiveness of a screening tool in adult cystic fibrosis diabetes** *Oral Presenter*: Hannah Burton, GB	14:00 - 14:00
EPS4.06	**Alterations in incretin and somatostatin levels by glucose tolerance status in people with cystic fibrosis** *Oral Presenter*: Bibi Uhre Nielsen, DK	14:00 - 14:00
EPS4.09	**Role for DPP4 inhibitor therapy in cystic fibrosis- related diabetes mellitus (CFRD)- experience from Manchester Adult Cystic Fibrosis Unit** *Oral Presenter*: Anjali Santhakumar, GB	14:00 - 14:00
EPS4.10	**Obstetric and neonatal outcomes in women with cystic fibrosis (wwCF) and diabetes in pregnancy** *Oral Presenter*: Amy Downes, GB	14:00 - 14:00

Poster Viewing
14:00 - 15:00

***PS1* - Poster Viewing 1**

P001	**A childhood, 16 years of cystic fibrosis (CF) Newborn Screening data in East London and beyond** *Oral Presenter*: Jacqui Cowlard, GB	14:00 - 14:00
P002	**Results from a clinical performance study of a new neonatal PAP screening ELISA kit for cystic fibrosis-newborn screening** *Oral Presenter*: Ana Marcão, PT	14:00 - 14:00
P003	**Clinical variability of the CFTR variant p.Arg117Cys uncovered by newborn screening for cystic fibrosis. Does the genetic background matter?** *Oral Presenter*: Emma Lundman, NO	14:00 - 14:00
P004	**Clinical consequences and functional impact of the rare S737F CFTR variant** *Oral Presenter*: Emanuela Pesce, IT	14:00 - 14:00
P005	**An audit on adherence to guidelines on screening colonoscopies in an adult cystic fibrosis centre** *Oral Presenter*: Fiona Hickey, IE	14:00 - 14:00
P008	**Critical Disease Burdens of Australian Adults with cystic fibrosis: results from an online survey** *Oral Presenter*: Anastasia Ward, AU	14:00 - 14:00
P009	**Development of a new information video for children about cystic fibrosis** *Oral Presenter*: Alison Taylor, GB	14:00 - 14:00
P010	**Establishing a collaboration between the 4 university children's hospitals in Egypt and the University of Michigan to improve cystic fibrosis care in Egypt** *Oral Presenter*: Samya Nasr, US	14:00 - 14:00
P011	**Late diagnosis of cystic fibrosis in adulthood in Republic of North Macedonia** *Oral Presenter*: Tatjana Jakovska Maretti,	14:00 - 14:00
P012	**The attitude towards prenatal cystic fibrosis diagnosis in Bulgaria** *Oral Presenter*: Guergana Petrova, BG	14:00 - 14:00
P013	**Tuberculosis or cystic fibrosis** *Oral Presenter*: Guergana Petrova, BG	14:00 - 14:00
P014	**Safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide cystic fibrosis therapeutic** *Oral Presenter*: Gili Hart, IL	14:00 - 14:00
P015	**Nebulizer selection and characterisation process with SPL84, an inhaled antisense oligonucleotide, supporting first in human clinical study in cystic fibrosis patients carrying the 3849 mutation** *Oral Presenter*: Gili Hart, IL	14:00 - 14:00
P019	**Complex CFTR allele [HB1] L467F-F508del is responsible**	14:00 - 14:00

	for poor clinical response to elexacaftor/tezacaftor/ivacaftor CFTRm therapy in a cystic fibrosis female with the L467F-F508del/621+1 G>T genotype: a case report *Oral Presenter*: Marcela Kreslová, CZ	
P020	**Therapy with elexacaftor/tezacaftor/ivacaftor in a patient with compound heterozygous *CFTR* mutation and the complex CFTR-allele *Phe508del; Leu467Phe*** *Oral Presenter*: Stephanie Thee, DE	14:00 - 14:00
P021	**Change in sweat chloride concentration following elexacaftor/Tezacaftor/ivacaftor in siblings with cystic fibrosis heterozygous for R334W / N1088D / R75Q mutations** *Oral Presenter*: Hisham A Saumtally, GB	14:00 - 14:00
P024	**Compound heterozygotes bearing the CFTRdup22 in *trans* with another cystic fibrosis-causing variant have a generally milder course of cystic fibrosis: analysis of 6 Czech cystic fibrosis cases** *Oral Presenter*: Andrea Holubová, CZ	14:00 - 14:00
P025	**Prevalence and clinical implications of the *p.Cys1400Ter* pathogenic *CFTR* mutation in Cyprus** *Oral Presenter*: Pinelopi Anagnostopoulou, CH	14:00 - 14:00
P027	**Mutational analysis of *CFTR* gene in Pakistani cystic fibrosis patients** *Oral Presenter*: Muhammad Usman Ghani, PK	14:00 - 14:00
P028	**Cystic fibrosis mutation pattern in 2019 in Albania: getting closer to the personalised therapy** *Oral Presenter*: Irena Kasmi, AL	14:00 - 14:00
P029	**Cystic fibrosis precision treatment – an unequal access in Brazil** *Oral Presenter*: Laís Mota, BR	14:00 - 14:00
P031	**Perspectives for gene therapy with the use of CFTR modulators in patients with cystic fibrosis** *Oral Presenter*: Luana da Silva Baptista Arpini, BR	14:00 - 14:00
P038	**Direct measurement of short-term adherence to elexacaftor/tezacaftor/ivacaftor and changes in sweat chloride levels – results from the RECOVER Study** *Oral Presenter*: Roy Gavin Stone, IE	14:00 - 14:00
P039	**Effect of elexacaftor/tezacaftor/ivacaftor (ETI) on sweat chloride levels in children with cystic fibrosis (CF) – a real-world experience** *Oral Presenter*: Yu Ling Tan, GB	14:00 - 14:00
P040	**Sweat chloride values in cystic fibrosis patients after one year on elexacaftor/tezacaftor/ivacaftor** *Oral Presenter*: Natalia Cirilli, IT	14:00 - 14:00
P041	**Correlation of improvements in sweat chloride and percent predicted FEV_1 across twenty studies examining different corrector therapies for F508del** *Oral Presenter*: Matthew Heneghan, GB	14:00 - 14:00

P042	**Nasal nitric oxide increases in patients with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor** *Oral Presenter*: Charlotte Olivia Pioch, DE	14:00 - 14:00
P043	**Changes in body composition in adult cystic fibrosis patients within six months of initiation elexacaftor/tezacaftor/ivacaftor therapy in Argentina** *Oral Presenter*: Lorena Mabel Tamburri, AR	14:00 - 14:00
P044	**Oral and intravenous antibiotic requirements prior to and following elexacaftor/tezacaftor/ivacaftor treatment in children and adults with cystic fibrosis – analysis from the RECOVER Study** *Oral Presenter*: Roy Gavin Stone, IE	14:00 - 14:00
P045	**Physical fitness of paediatric cystic fibrosis patients in the era of CFTR modulators** *Oral Presenter*: Laura Antonia Stöger, AT	14:00 - 14:00
P046	**Early parameters to predict long-term efficacy of CFTR modulators in patients with cystic fibrosis** *Oral Presenter*: Pascal Heer, CH	14:00 - 14:00
P049	**Effects of elexacaftor/tezacaftor/ivacaftor after 6 months in Dutch people with cystic fibrosis with at least 1 F508del mutation** *Oral Presenter*: Inez Bronsveld, NL	14:00 - 14:00
P050	**Elexacaftor/tezacaftor/ivacaftor for adult cystic fibrosis patients with preserved lung function: a case series** *Oral Presenter*: Zisis Balmpouzis, CH	14:00 - 14:00
P051	**Real-world experience of change in lung clearance index ($LCI_{2.5}$) following initiation of elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis aged 6 through 11** *Oral Presenter*: Heather Dowle, GB	14:00 - 14:00
P052	**Efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with normal/near normal FEV_1 (≥70%)** *Oral Presenter*: Galit Livnat, IL	14:00 - 14:00
P053	**Spirometric and anthropometric improvements in response to elexacaftor/tezacaftor/ivacaftor depend on age and lung disease severity** *Oral Presenter*: Katharina Schütz, DE	14:00 - 14:00
P054	**Long-term efficacy and safety of elexacaftor/tezacaftor/ivacaftor (ETI) in people with cystic Fibrosis (pwCF) ≥ 50 years of age in a real-world setting** *Oral Presenter*: Matthias Welsner, DE	14:00 - 14:00
P055	**No impact of elexacaftor/tezacaftor/ivacaftor (ETI) CFTRm therapy on male infertility due to CBAVD in two adult cystic fibrosis patients: case report** *Oral Presenter*: Nela Stastna, CZ	14:00 - 14:00
P056	**Impact of CFTR Modulator Therapy on sleep parameters in a small cohort of cystic fibrosis patients** *Oral Presenter*: Joana Guimarães, PT	14:00 - 14:00

P057	**Sustained Effectiveness of elexacaftor/tezacaftor/ivacaftor in lung transplant candidates with cystic fibrosis** *Oral Presenter*: Filia Diamantea, GR	14:00 - 14:00
P058	**New algorithm proposal to allow elexacaftor/tezacaftor/ivacaftor use for patients under 18 with liver dysfunction** *Oral Presenter*: Tiphaine BIHOUEE, FR	14:00 - 14:00
P059	**Therapeutic drug monitoring of elexacaftor/tezacaftor/ivacaftor over 1 year in adult patients with cystic fibrosis** *Oral Presenter*: Susanne Naehrig, DE	14:00 - 14:00
P060	**Measurement of the plasma concentration of elexacaftor/tezacaftor/ivacaftor (ETI) by LC/MS-MS in a patient with cystic fibrosis during pregnancy** *Oral Presenter*: Mauro Leucio Mattei, IT	14:00 - 14:00
P061	**FTR-Modulator therapy during pregnancy in a mother with F508del carrier status and high-grade suspicion of cystic fibrosis in the foetus** *Oral Presenter*: Stephanie Thee, DE	14:00 - 14:00
P062	**The impact of elexacaftor/tezacaftor/ivacaftor on adherence to inhaled medication in adults with cystic fibrosis: a 3-centre study in Greece** *Oral Presenter*: Katerina Manika, GR	14:00 - 14:00
P063	**Dermatological reactions to elexacaftor/tezacaftor/ivacaftor: experience within a regional adult cystic fibrosis centre** *Oral Presenter*: Akhil P Sawant, GB	14:00 - 14:00
P064	**Bilateral cataracts in an adolescent following the use of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies** *Oral Presenter*: Pauline Singleton, GB	14:00 - 14:00
P065	**A Brazilian experience of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying at least one copy of F508del-CFTR** *Oral Presenter*: Miquéias Lopes-Pacheco, PT	14:00 - 14:00
P066	**Single center experience of patients using modulatory therapy** *Oral Presenter*: GÖKÇEN ÜNAL, TR	14:00 - 14:00
P067	**Real-life data of lumacaftor/ivacaftor therapy in children with cystic fibrosis homozygous for F508del with emphasis on small airway disease in the Netherlands** *Oral Presenter*: Annelies M. Zwitserloot, NL	14:00 - 14:00
P068	**Real-life experience with a generic formulation of lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for the Phe508del *CFTR* mutation** *Oral Presenter*: Alejandro Teper, AR	14:00 - 14:00
P069	**Effect of Orkambi therapy on the lung microbiota in people with cystic fibrosis (PwCF) over the first 12 months of therapy (ROCK Study)**	14:00 - 14:00

	Oral Presenter: Gisli Einarsson, GB	
P070	**Lumacaftor/ivacaftor combination for cystic fibrosis patients in Bulgaria** *Oral Presenter*: Guergana Petrova, BG	14:00 - 14:00
P071	**Evaluation of CFTR modulator efficacy by rectal organoid morphology analysis (ROMA) indexes** *Oral Presenter*: Senne Cuyx, BE	14:00 - 14:00
P073	**Clinical efficacy of CFTR modulator therapy in patients carrying the I1234V mutation** *Oral Presenter*: Bat El Bar Aluma, IL	14:00 - 14:00
P074	**Treatment effects of CFTR modulators on people with cystic fibrosis carrying the Georgian mutation (Q359K/T360K)** *Oral Presenter*: Karin Yaacoby-Bianu,	14:00 - 14:00
P075	**Discrepancy between *in vitro* CFTR functional analysis and clinical response to elexacaftor/tezacaftor/ivacaftor (ETI) in a homozygous S364P (c.1090T>C) patient with cystic fibrosis** *Oral Presenter*: Arthur de SEVIN, FR	14:00 - 14:00
P076	**Complex CFTR allele L467F-F508del: *in vitro* and clinical response to CFTR modulators** *Oral Presenter*: Eva Furstova, CZ	14:00 - 14:00
P077	**Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation** *Oral Presenter*: Malena Cohen-Cymberknoh, IL	14:00 - 14:00
P078	**Case report: elexacaftor/tezacaftor/ivacaftor as a game changer in an individual with CFTR class II mutation N1303k** *Oral Presenter*: Livia Mia Gona-Hoepler, AT	14:00 - 14:00
P079	**Personalized CFTR modulator therapy for G85E and N1303K homozygous patients with cystic fibrosis** *Oral Presenter*: Simon Graeber, DE	14:00 - 14:00
P080	**Improved clinical outcomes following ivacaftor treatment in a cystic fibrosis patient homozygous for 3272-26A>G variant** *Oral Presenter*: Jasna Rodman Berlot, SI	14:00 - 14:00
P081	**Theratyping – extending the success of highly effective CFTR modulators to rare mutations** *Oral Presenter*: Mordechai Pollak, IL	14:00 - 14:00
P082	**Is the new modulator affecting global health outcomes over time?** *Oral Presenter*: Sonia Graziano, IT	14:00 - 14:00
P083	**Inequal access to CFTR modulators across ECFS-CTN countries** *Oral Presenter*: Fiona Dunlevy, DK	14:00 - 14:00
P084	**Willingness of people treated with elexacaftor/tezacaftor/ivacaftor (ETI) to participate in**	14:00 - 14:00

	randomized clinical trials of new modulators and inhaled antibiotics *Oral Presenter*: Donald VanDevanter, US	
P085	**Attitudes to clinical trial participation in the post Kaftrio®era: reasons to be cheerful...** *Oral Presenter*: Alison Lynne Hopkins, GB	14:00 - 14:00
P086	**The French clinical research network in cystic fibrosis: more than 10 years of positive experience in clinical research for patients** *Oral Presenter*: Alexandre Coudrat, FR	14:00 - 14:00
P087	**Levelling the playing field through the London Network of the UK Clinical Trials Accelerator Platform** *Oral Presenter*: Sophie Pinnell, GB	14:00 - 14:00
P088	**A systematic review on all efficacy endpoints used in cystic fibrosis clinical trials in the past 5 years** *Oral Presenter*: Marlou Bierlaagh, NL	14:00 - 14:00
P089	**Research priorities in cystic fibrosis: refreshing the James Lind Alliance top ten** *Oral Presenter*: Alan Smyth, GB	14:00 - 14:00
P090	**Treatment use among SIMPLIFY trial participants through 24 weeks of follow-up** *Oral Presenter*: Alex H. Gifford, US	14:00 - 14:00
P091	**Development and validation of revised treatment adherence and adherence barrier questionnaires for children with cystic fibrosis aged 6 through 11** *Oral Presenter*: Sharon Sutton, IE	14:00 - 14:00
P092	**Preliminary observations of treatment and symptom reporting in the Home-Reported Outcomes in cystic fibrosis study (HERO-2)** *Oral Presenter*: Cynthia Brown, US	14:00 - 14:00
P093	**The effect quality of life on cystic fibrosis children patients in Gaza Strip** *Oral Presenter*: Asem Altorok, PS	14:00 - 14:00
P094	**A Phase II study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of BI 1291583 in patients with cystic fibrosis bronchiectasis (the Clairafly™ study)** *Oral Presenter*: Marcus Mall, DE	14:00 - 14:00
P095	**A phase 1b/2a randomized, double-blind, placebo-controlled, multi-centre study evaluating nebulized phage therapy in cystic fibrosis subjects with chronic *Pseudomonas aeruginosa* pulmonary infection** *Oral Presenter*: Urania Rappo, US	14:00 - 14:00
P096	**Effect of acute systemic corticosteroids on clinical outcomes in cystic fibrosis pulmonary exacerbations** *Oral Presenter*: Oliver James McElvaney, US	14:00 - 14:00
P097	**Assessment of intrapulmonary percussive ventilation on the**	14:00 - 14:00

	rheology of bronchial secretions *Oral Presenter*: Jérémy Patarin, FR	
P098	**Longitudinal follow-up of exacerbated cystic fibrosis patients with sputum rheology** *Oral Presenter*: Jérémy Patarin, FR	14:00 - 14:00
P099	**Effect of a mucolytic agent delivered through sinus pulsating aerosol system (SPAS) device on sinonasal symptoms and patient report outcomes in people with cystic fibrosis (PwCF)** *Oral Presenter*: Mari Nieves Balaguer Cartagena, ES	14:00 - 14:00
P100	**Undergraduate research-based education for identifying new treatment options for cystic fibrosis** *Oral Presenter*: Nikki Scheen, NL	14:00 - 14:00
P227	**Real-world, single-centre evaluation of the efficacy of postal lower airway microbiology samples** *Oral Presenter*: Edward Sizer, GB	14:00 - 14:00
P228	***In vitro evolution of levofloxacin resistance in lineages of clinical Pseudomonas aeruginosa isolates cultured at different stages of infection from people with cystic fibrosis*** *Oral Presenter*: Callum Matthew Sloan, GB	14:00 - 14:00
P229	**Lung and gut microbiome modifications after prolonged Kaftrio® treatment** *Oral Presenter*: Carlo Castellani, IT	14:00 - 14:00
P230	**The microbiome of cystic fibrosis (CF) sputum and its association with incident *Stenotrophomonas maltophilia* (SM) infections** *Oral Presenter*: Lauren Bowron, CA	14:00 - 14:00
P231	**Monitoring of respiratory tract infections of cystic fibrosis transplanted patients by means of a multiplex PCR assay** *Oral Presenter*: Cristina Fevola*, IT	14:00 - 14:00
P232	**Analysis of the lung microbiome in cystic fibrosis patients using 16s sequencing** *Oral Presenter*: Manasvi Pinnaka, US	14:00 - 14:00
P233	**Wanted: *Pseudomonas* and *Staphylococcus* - new diagnostic approaches in cystic fibrosis! Is *16S rRNA gene sequencing* an equivalent diagnostic tool to *conventional microbiology*?** *Oral Presenter*: Rebecca Luise Knoll, DE	14:00 - 14:00
P234	**Investigating the role of hypoxia in driving the adaptation of *Mycobacterium abscessus* infection in cystic fibrosis** *Oral Presenter*: Niamh Duggan, IE	14:00 - 14:00
P235	**Pharmacological activation of NRF2 has protective effects during *Mycobacterium abscessus* infection by promoting host defences and reducing inflammatory damage in the context of cystic fibrosis** *Oral Presenter*: Audrey Bernut, FR	14:00 - 14:00
P236	**Siderophore production by the emerging cystic fibrosis pathogens of the genus *Achromobacter***	14:00 - 14:00

	Oral Presenter: Pauline Sorlin, FR	
P237	***Stenotrophomonas maltophilia* isolates from cystic fibrosis patients eliminate competitor bacteria** *Oral Presenter*: Cristian Crisan, US	14:00 - 14:00
P238	**Host-pathogen interactions in the era of antimicrobial resistance** *Oral Presenter*: Ruggero La Rosa, DK	14:00 - 14:00
P239	**Bacterial interactions in *Pseudomonas aeruginosa* and *Achromobacter xylosoxidans* co-cultures** *Oral Presenter*: Cecilia Sahl, SE	14:00 - 14:00
P240	**Lower levels of bacterial aerobic respiration in sputum from people with cystic fibrosis with chronic lung infection** *Oral Presenter*: Peter Østrup Jensen, DK	14:00 - 14:00
P241	**Using an *in vitro* model to investigate the microbiomes of people with cystic fibrosis** *Oral Presenter*: Katrine Madsen, DK	14:00 - 14:00
P242	**Small colony variants of *Staphylococcus aureus* often exhibit a mucoid phenotype in the airways of people with cystic fibrosis** *Oral Presenter*: Christine Rumpf, DE	14:00 - 14:00
P243	**The effect of hypoxic conditions on *Burkholderia cenocepacia* clinical isolates from individuals with cystic fibrosis** *Oral Presenter*: Ciaran Carey, IE	14:00 - 14:00
P244	**The impact of CFTR modulators on positive Pseudomonas aeruginosa (Pa) culture and antibiotic susceptibility in adults with cystic fibrosis** *Oral Presenter*: Natalya Ellis, GB	14:00 - 14:00
P245	**Real-world elexacaftor/tezacaftor/ivacaftor(ETI) changes prospective sputum collection and microbiological reporting in a single centre pilot cystic fibrosis cohort.** *Oral Presenter*: Kevin Deasy, IE	14:00 - 14:00
P246	**Being positive: Assessing the effect of CFTR modulator therapy on sputum sampling and bacterial growth at the All Wales Adult Cystic Fibrosis Centre** *Oral Presenter*: Charlotte Addy, GB	14:00 - 14:00
P247	**ETI reduces antibiotic treatment days in people with cystic fibrosis – a real-life observation.n** *Oral Presenter*: Krystyna Poplawska, DE	14:00 - 14:00
P248	**Antimicrobial activity of dry powder liposomal loaded rifampicin against *Mycobacterium abscessus* complex respiratory isolates** *Oral Presenter*: Mona Alhamod, GB	14:00 - 14:00
P249	***In vitro* activity of liposomal loaded apramycin against *Pseudomonas aeruginosa* respiratory isolates** *Oral Presenter*: Renlong Na, GB	14:00 - 14:00
P250	**Minimum inhibitory concentration targeted antibiotic dose**	14:00 - 14:00

	optimization in patients with cystic fibrosis *Oral Presenter*: David Young, US	
P251	**Susceptibility to cefiderocol of an accurately identified collection of 110 *Achromobacter* strains from cystic fibrosis patients** *Oral Presenter*: Vincent JEAN-PIERRE, FR	14:00 - 14:00
P252	**Proposed plan for oxygen therapy as an adjuvant to antibiotics in cystic fibrosis** *Oral Presenter*: Michael Tunney, GB	14:00 - 14:00
P253	**Optimisation of inhaled antibiotic prescribing for *Pseudomonas aeruginosa* infections in people with cystic fibrosis: Further insights from Principal Investigators of the ECFS Clinical Trials Network** *Oral Presenter*: Callum Matthew Sloan, GB	14:00 - 14:00
P254	**Clinical effects of *Achromobacter xylosoxidans* in patients with cystic fibrosis** *Oral Presenter*: Seyda Karabulut, TR	14:00 - 14:00
P255	**Risk and time to reinfection with *Pseudomonas aeruginosa* (Pa) according to the management of Pa infection in children with cystic fibrosis** *Oral Presenter*: Guillaume Thouvenin, FR	14:00 - 14:00
P256	**Impact of COVID-19 pandemic and introduction of CFTR modulator therapy on sputum sampling in a large adult cystic fibrosis (CF) unit** *Oral Presenter*: Katie Gaffney, GB	14:00 - 14:00
P257	**Microbiological characterisation of methicillin-resistant *Staphylococcus aureus* isolates recovered from cystic fibrosis people during two Spanish multicentre studies (2013 - 2021)** *Oral Presenter*: Ainhize Maruri-Aransolo, ES	14:00 - 14:00
P258	**Phenotypic and gene expressional changes of *Pseudomonas aeruginosa* isolates from cystic fibrosis patient airways upon estradiol exposure** *Oral Presenter*: Mareike Müller, DE	14:00 - 14:00
P259	**Inevitability of treatment after culturing *Mycobacterium abscessus* complex (MABSC) in cystic fibrosis** *Oral Presenter*: Nicholas Wilson, GB	14:00 - 14:00
P260	**Co-culture of *Prevotella spp.* and *Pseudomonas aeruginosa* from chronic cystic fibrosis infection in artificial sputum medium** *Oral Presenter*: Enna E. Gibson, GB	14:00 - 14:00
P261	**Detection of viable but non culturable *Stenotrophomonas maltophilia* in cystic fibrosis sputum samples: evidence and perspectives** *Oral Presenter*: Natalia Cirilli, IT	14:00 - 14:00
P262	**Respiratory microbiological patterns and comparison in patients with CFTR-related disorders, cystic fibrosis and non-cystic fibrosis bronchiectasis**	14:00 - 14:00

	Oral Presenter: Gregorio Basile, IT	
P263	**Are cystic fibrosis patients displaying exacerbation symptoms when they culture new pathogens on respiratory samples?** *Oral Presenter*: Paul Wilson, GB	14:00 - 14:00
P264	***Pseudomonas aeruginosa* (P. aeruginosa) – a review of seasonal patterns and symptom presentation for first and new growths** *Oral Presenter*: Omar Lamptey, GB	14:00 - 14:00
P265	**Fast-track biomarker "Anti-Exophiala IgG" in suspected Exophiala spp. infection** *Oral Presenter*: Carsten Schwarz, DE	14:00 - 14:00
P266	**Genomic and phenotypic comparisons of *Pseudomonas aeruginosa* ST27 strains isolated from respiratory tract and domestic environment of a cystic fibrosis patient** *Oral Presenter*: Chloé Dupont, FR	14:00 - 14:00
P267	***In vitro* efficacy of inhalative antibiotics against *Pseudomonas aeruginosa* using artificial sputum medium** *Oral Presenter*: Michael Hogardt, DE	14:00 - 14:00
P268	**Outcomes after first *Pseudomonas aeruginosa* (Pa) isolate in cystic fibrosis (CF) patients 2018-2022** *Oral Presenter*: Ailbhe Marie Murphy, IE	14:00 - 14:00
P269	**Proposed plan for oxygen therapy as an adjuvant to antibiotics in cystic fibrosis** *Oral Presenter*: Mette Kolpen, DK	14:00 - 14:00
P270	**The prevalence of *Candida dubliniensis* in cystic fibrosis - a cross sectional, one-year, single centre study** *Oral Presenter*: Emily Krantz, SE	14:00 - 14:00
P271	**Impact of Achromobacter spp isolation on lung function in children, a retrospective case-control study** *Oral Presenter*: Nevine Antoun, FR	14:00 - 14:00
P272	**Methicillin-resistant *Staphylococcus aureus* eradication regimens for children and adults with cystic fibrosis** *Oral Presenter*: Rebecca Boyle, US	14:00 - 14:00
P273	**Chronic airway infection and resistance pattern in children and adults with cystic fibrosis in Oman. A single centre cross sectional study** *Oral Presenter*: Amjad Al Haddabi, OM	14:00 - 14:00
P274	**Identification of $bla_{\text{OXA-23}}$ in a mucoid XDR *Acinetobacter baumannii* isolated from a patient with cystic fibrosis** *Oral Presenter*: Martina Rossitto, IT	14:00 - 14:00
P275	**Prevalence of *Pseudomonas aeruginosa* infection over a five-year period in Albanian children with cystic fibrosis** *Oral Presenter*: Irena Kasmi, AL	14:00 - 14:00
P276	**Updating the consensus document: laboratory standards for processing microbiological samples from people with cystic fibrosis**	14:00 - 14:00

	Oral Presenter: Rishi Dhillon, GB	
P277	**A survey of UK cystic fibrosis centres regarding stopping anti-*Pseudomonas aeruginosa* (PA) nebulised therapy in children who become free from Pa infection** *Oral Presenter*: Francis Gilchrist, GB	14:00 - 14:00
P278	**Partnering for impact: the cystic fibrosis antimicrobial resistance syndicate** *Oral Presenter*: CONSTANCE TAKAWIRA, GB	14:00 - 14:00
P279	**Infectious status and lung clearance index** *Oral Presenter*: Mihaela Dediu, RO	14:00 - 14:00
P280	**Identification of infection risk areas in the domestic environment by members of the cystic fibrosis community** *Oral Presenter*: Shannon Taylor Venus, GB	14:00 - 14:00
P281	**Children with cystic fibrosis demonstrate high rates of asymptomatic carriage of Clostridioides difficile** *Oral Presenter*: Keith Chee Y. Ooi, AU	14:00 - 14:00
P282	**Implementing routine assessment of gastrointestinal outcome measures in the cystic fibrosis clinic** *Oral Presenter*: Aleksandra Duffy, GB	14:00 - 14:00
P283	**Evaluation of cystic fibrosis-related liver disease in a paediatric cohort** *Oral Presenter*: Saioa Vicente Santamaría, ES	14:00 - 14:00
P284	**Assessing the potential of the FIB-4 index as a screening tool for advanced liver fibrosis in an adult cystic fibrosis population** *Oral Presenter*: Stephen Armstrong, GB	14:00 - 14:00
P285	**Clinical and genetic risk factors for cystic fibrosis-related liver disease in Egyptian cystic fibrosis children** *Oral Presenter*: Samya Nasr, US	14:00 - 14:00
P287	**Characterisation of *CFTR* mutations in people with cystic fibrosis and severe liver disease who are not eligible for CFTR modulators** *Oral Presenter*: Carla Colombo, IT	14:00 - 14:00
P288	**The effects of stopping ursodeoxycholic acid in adult patients with mild cystic fibrosis-related liver disease (CFLD)** *Oral Presenter*: Zaina Aloul, GB	14:00 - 14:00
P289	**Intestinal obstruction syndromes in cystic fibrosis** *Oral Presenter*: Alan Anderson, GB	14:00 - 14:00
P291	**Screening for Coeliac Disease in adults with cystic fibrosis in Wales** *Oral Presenter*: Dawn Lau, GB	14:00 - 14:00
P292	**The effectiveness of pre-colonoscopy bowel preparation for colorectal cancer screening in patients with cystic fibrosis**	14:00 - 14:00

	in Wales *Oral Presenter*: Anna Sayers, GB	
P293	**An intensive protocol for bowel preparation in people with cystic fibrosis undergoing screening colonoscopy, a single centre experience** *Oral Presenter*: Tal Lavi, IL	14:00 - 14:00
P294	**Colorectal cancer screening in cystic fibrosis, what can iFOBT tell us?** *Oral Presenter*: Nicole Taylor, AU	14:00 - 14:00
P295	**The results of colorectal cancer screening in patients with cystic fibrosis in Wales** *Oral Presenter*: Anna Sayers, GB	14:00 - 14:00
P296	**Presentation, characteristics and management of obstructive intestinal conditions in cystic fibrosis** *Oral Presenter*: Caitlin Miles, AU	14:00 - 14:00
P297	**Dual delivery microbial enzymatic product as alternative PERT for cystic fibrosis patients** *Oral Presenter*: Miguel Angel Poza, ES	14:00 - 14:00
P298	**Gastroenterology services for patients with cystic fibrosis across Australia and New Zealand: a multi-stakeholder assessment of patients' and professionals' perspectives** *Oral Presenter*: Tamarah Katz, AU	14:00 - 14:00
P299	**Assessing dynamics of abdominal symptoms during a new therapy with elexacaftor/tezacaftor/ivacaftor using the new CFAbd-day2day© questionnaire** *Oral Presenter*: Jochen Mainz, DE	14:00 - 14:00
P300	**The effect of Highly Effective Modulator therapy (HEMT) on liver function tests of adult patients with cystic fibrosis-related liver disease at one year: the Welsh experience** *Oral Presenter*: Zaina Aloul, GB	14:00 - 14:00
P302	**Faecal calprotectin and elastase concentrations in patients before and after treatment with CFTR modulators** *Oral Presenter*: Katarzyna Zybert, PL	14:00 - 14:00
P303	**Real-life data for liver function in children on CFTR-modulators in Bulgaria** *Oral Presenter*: Guergana Petrova, BG	14:00 - 14:00
P304	**Oral glucose tolerance test in diagnosis of cystic fibrosis-related diabetes in the era of continuous glucose monitoring** *Oral Presenter*: Anjali Santhakumar, GB	14:00 - 14:00
P306	**Changes in glucose tolerance in people with cystic fibrosis after initiation of first-generation CFTR modulator treatment** *Oral Presenter*: Rikke Spragge Ekblond, DK	14:00 - 14:00

P307	**Updating the consensus document 'Management of cystic fibrosis diabetes' published by Cystic Fibrosis Trust** *Oral Presenter*: Jacqueline Ali, GB	14:00 - 14:00
P308	**Strategies for the screening of glucose tolerance abnormalities and diabetes in people with cystic fibrosis: a French position statement** *Oral Presenter*: Laurence Weiss, FR	14:00 - 14:00
P309	**UK cystic fibrosis physiotherapists' knowledge and understanding of cystic fibrosis-related diabetes in relation to physical activity and exercise-national survey** *Oral Presenter*: Harbinder Sunsoa, GB	14:00 - 14:00
P310	**Patient experience of a novel CFRD education clinic** *Oral Presenter*: Laura Kinsey, GB	14:00 - 14:00
P311	**Pregnancy in cystic fibrosis – extending the role of the cystic fibrosis pharmacist in the modulator era** *Oral Presenter*: Elaine Bowman, GB	14:00 - 14:00
P312	**Provider perspectives and practices related to sexual and reproductive care provision for males with cystic fibrosis** *Oral Presenter*: Traci Kazmerski, US	14:00 - 14:00
P313	**An overview of body composition and metabolic markers in adults with cystic fibrosis: a single centre analysis** *Oral Presenter*: Clodagh Landers, IE	14:00 - 14:00
P314	**Cystic fibrosis related to bone disease in children: can it be predicted?** *Oral Presenter*: Ismail Guzelkas, TR	14:00 - 14:00
P315	**Bone mineral density in children and adolescents with cystic fibrosis** *Oral Presenter*: Gizem Tamer, NL	14:00 - 14:00
P316	**Handgrip strength among children with cystic fibrosis: is there a correlation with lung function?** *Oral Presenter*: Elpis Hatziagorou, GR	14:00 - 14:00
P317	**Effect of high intensity interval training versus moderate intensity continuous training on appetite control in people with cystic fibrosis – a randomized controlled study** *Oral Presenter*: Jana Koop, DE	14:00 - 14:00
P318	**Weight and vitamin D changes in adults with cystic fibrosis in the West of Scotland post induction of triple therapy during a global pandemic** *Oral Presenter*: Fiona Moore, GB	14:00 - 14:00
P319	**Effects of elexacaftor/tezacaftor/ivacaftor (ETI) on nutrition parameters and resting energy expenditure (REE) in people with cystic fibrosis (pwCF)** *Oral Presenter*: Lenny Sasse, DE	14:00 - 14:00
P320	**Comparing faecal elastase, pancreatic enzyme doses, HbA1c and insulin doses in adult cystic fibrosis patients pre- and 6 months post-commencement of Kaftrio®** *Oral Presenter*: Lidia Sheibani, GB	14:00 - 14:00

P321	**Impact of short-term CFTR modulators treatment on changes in nutritional and glucose status in cystic fibrosis paediatric patients with different glucose tolerance** *Oral Presenter*: Monika Mielus, PL	14:00 - 14:00
P322	**Lipid profiles in a Scottish adult cystic fibrosis (CF) centre - prevalence and significance in an aging population** *Oral Presenter*: Lianne Robb, GB	14:00 - 14:00
P323	**Does elexacaftor/tezacaftor/ivacaftor triple therapy significantly raise blood lipids? A longitudinal cohort study** *Oral Presenter*: Ronan Docherty, GB	14:00 - 14:00
P324	**Essential fatty acid deficiency in children and young adults with cystic fibrosis – micronutrient assessment is still an actual topic** *Oral Presenter*: Marcela Kreslová, CZ	14:00 - 14:00
P325	**A paradigm shift in cystic fibrosis nutritional care: clinicians views on the management of patients with overweight and obesity** *Oral Presenter*: Joanna Snowball, GB	14:00 - 14:00
P326	**Impact of the elexacaftor/tezacaftor/ivacaftor on the nutrition parameters and gastrointestinal symptoms in adult cystic fibrosis patients in the cystic fibrosis centre of Brno, Czech Republic** *Oral Presenter*: Nela Stastna, CZ	14:00 - 14:00
P327	**Cross-cultural adaptation and measurement properties of the Brazilian version of the Knowledge of Disease Management-CF-Adolescent questionnaire** *Oral Presenter*: Hilda Angelica Iturriaga-Jimenez, BR	14:00 - 14:00
P329	**Audit of change in weight and BMI centile in children on elexacaftor/tezacaftor/ivacaftor in the Liverpool paediatric cystic fibrosis population** *Oral Presenter*: Clare J Woodland, GB	14:00 - 14:00
P330	**One-year assessment of body composition in cystic fibrosis patients on elexacaftor/texacaftor/ivacaftor** *Oral Presenter*: Veronica Zamponi, IT	14:00 - 14:00
P331	**What nutritional advice is being given to people with cystic fibrosis and hepatic steatosis?** *Oral Presenter*: Maeve O'Driscoll, GB	14:00 - 14:00
P332	**Description of nutritional status in a cohort of paediatric patients with cystic fibrosis analysis of body composition changes after initiation of treatment with elexacaftor/tezacaftor/ivacaftor** *Oral Presenter*: Saioa Vicente Santamaría, ES	14:00 - 14:00
P333	**Refresh: patient experience of an online healthy eating webinar designed specifically for adults with cystic fibrosis on CFTR modulators** *Oral Presenter*: Katie Marsden, GB	14:00 - 14:00

P334	**Body composition changes after elexacaftor/tezacaftor/ivacaftor treatment in adults with cystic fibrosis – single centre experience** *Oral Presenter*: Andrea Vukić Dugac, HR	14:00 - 14:00
P335	**Survey of oral health survey in children in a secondary paediatric cystic fibrosis service** *Oral Presenter*: Naveen Rao, GB	14:00 - 14:00
P336	**Evolution of the body composition of people with cystic fibrosis 6 months after the introduction of treatment with exacaftor/tezacaftor/ivacaftor (ETI)** *Oral Presenter*: Camille Audousset, FR	14:00 - 14:00
P337	**Bone health status and audit of DEXA scan frequency of adults with cystic fibrosis at a UK centre** *Oral Presenter*: Eliza C Tassone, GB	14:00 - 14:00
P338	**Body composition in children with cystic fibrosis receiving triple combination therapy** *Oral Presenter*: Uros Krivec, SI	14:00 - 14:00
P339	**Diet quality assessment of adults with cystic fibrosis - comparison to population dietary guidelines: a cross-sectional study** *Oral Presenter*: Cian Greaney, IE	14:00 - 14:00
P340	**The impact of modulators on faecal elastase in children with cystic fibrosis** *Oral Presenter*: Elizabeth Sheppard, GB	14:00 - 14:00
P341	**Pancreatic status and enzyme usage in the age of CFTR modulator treatment** *Oral Presenter*: Eliza C Tassone, GB	14:00 - 14:00
P342	**Serum sodium, chloride and potassium levels after start CFTR modulators treatment in CF pediatric patients** *Oral Presenter*: Monika Mielus, PL	14:00 - 14:00
P343	**Combination vitamin supplementation therapy in children with cystic fibrosis** *Oral Presenter*: Anirban Maitra, GB	14:00 - 14:00
P344	**How should Pancreatic Enzyme Replacement Therapy (PERT) be administered to infants?** *Oral Presenter*: Eleanor McGray, GB	14:00 - 14:00
P406	**Effects of the treatment with elexacaftor/tezacaftor/ivacaftor on aerobic fitness of adolescents with cystic fibrosis** *Oral Presenter*: Marcio Vinicius Fagundes Donadio, BR	14:00 - 14:00
P407	**Physical activity and sedentary behavior in cystic fibrosis patients before and after triple modulator therapy: a single-centre retrospective study** *Oral Presenter*: Anna Barrero, FR	14:00 - 14:00
P408	**The effect of major life changes on exercise and physical activity in people with cystic fibrosis** *Oral Presenter*: Owen William Tomlinson, GB	14:00 - 14:00

P409	**Monitoring adherence to nebulised therapies during the first UK lockdown and school closure period of the COVID-19 pandemic in children with cystic fibrosis** *Oral Presenter*: Charlotte Smith, GB	14:00 - 14:00
P410	**The impact of the COVID 19 pandemic and modulator therapy on routine respiratory sampling in paediatric cystic fibrosis (CF)** *Oral Presenter*: Bethany Millman, GB	14:00 - 14:00
P411	**Thinking out of the box: twinning in the era of the COVID-19 pandemic** *Oral Presenter*: Simona Mosescu, RO	14:00 - 14:00
P412	**A patient-led review of outpatient services following the COVID-19 pandemic and widespread introduction of highly-effective modulator treatments and remote monitoring devices** *Oral Presenter*: Jocelyn Choyce, GB	14:00 - 14:00
P413	**How to use telemonitoring for the detection of respiratory exacerbations in cystic fibrosis: effectiveness and adherence** *Oral Presenter*: Letizia Luciani, IT	14:00 - 14:00
P414	**The effect of elexacaftor/tezacaftor/ivacaftor on functional capacity in children with cystic fibrosis** *Oral Presenter*: Sophia Ward, GB	14:00 - 14:00
P415	**A service evaluation to quantify real-world spirometry grading and frequency data following the introduction of the NuvoAir Air Next lung function device in one UK cystic fibrosis (CF) centre** *Oral Presenter*: Jamie Watkins, GB	14:00 - 14:00
P416	**Self-reported levels of physical activity do not give an accurate insight into the habitual levels of physical activity in children and young people with cystic fibrosis** *Oral Presenter*: Helen Douglas, GB	14:00 - 14:00
P418	**Patient satisfaction and clinical effectiveness of using the I-neb in children with cystic fibrosis (CF) in Wales** *Oral Presenter*: Kathryn G Welsh, GB	14:00 - 14:00
P419	**Lung deposition of nebulized drug using favorite nebulisation compared to mesh nebuliser in healthy and cystic fibrosis patients: a randomised cross-over trial** *Oral Presenter*: Anne-Sophie Aubriot, BE	14:00 - 14:00
P420	**A pilot study looking at gamification to improve the experience of airway clearance for children with cystic fibrosis** *Oral Presenter*: Adam Walsh, GB	14:00 - 14:00
P421	**Use of mechanical insufflation-exsufflation in children with**	14:00 - 14:00

	cystic fibrosis *Oral Presenter*: Kieren James Lock, GB	
P422	**PEPing up your physio: how manometers improve adherence to airway clearance techniques (ACT) in children with chronic respiratory disease** *Oral Presenter*: Rachel Hawes, GB	14:00 - 14:00
P423	**A low-cost positive expiratory pressure device for people with cystic fibrosis in developing countries** *Oral Presenter*: Jamie Wood, US	14:00 - 14:00
P424	**Short-term effects of positive expiratory pressure on peripheral ventilation inhomogeneity in children with cystic fibrosis: a randomised sham-controlled crossover study** *Oral Presenter*: Simone Gambazza, IT	14:00 - 14:00
P425	**Identifying barriers to completing chest physiotherapy in the early years** *Oral Presenter*: Melissa Richmond, CA	14:00 - 14:00
P426	**The management of musculoskeletal issues in cystic fibrosis: the respiratory physiotherapists' perspective** *Oral Presenter*: Stephanie Graham, GB	14:00 - 14:00
P427	**Evaluating the provision of exercise for in-patients with cystic fibrosis across cystic fibrosis centres in the UK and identification of challenges and barriers surrounding delivery of care** *Oral Presenter*: Stephanie Graham, GB	14:00 - 14:00
P428	**An evaluation of the current Manchester Adult Cystic Fibrosis Centre (MACFC) exercise service** *Oral Presenter*: Nicole Petch, GB	14:00 - 14:00
P429	**The first UK cystic fibrosis trust exercise practitioner fellowship - an insight for the future provision of exercise services among individuals with cystic fibrosis and healthcare professionals** *Oral Presenter*: Lucia Diego-Vicente, GB	14:00 - 14:00
P430	**Are physical activity levels in children with cysic fibrosis associated to adherence to treatment?** *Oral Presenter*: Kieren James Lock, GB	14:00 - 14:00
P431	**Factors related to higher level of physical activity in Swedish cystic fibrosis-patients – a registry-based cross sectional study** *Oral Presenter*: Sofia Wilhelmsson, SE	14:00 - 14:00
P432	**Physical working capacity and health-related quality of life in adolescents and adult people with cystic fibrosis in Sweden** *Oral Presenter*: Karolina Wallin, SE	14:00 - 14:00
P433	**Association of physical activity with quadriceps force and functional performance in children with cystic fibrosis and healthy peers** *Oral Presenter*: Manon Kinaupenne, BE	14:00 - 14:00

P434	**Exploring cystic fibrosis patients' attitudes and beliefs regarding exercise participation during hospitalization at a regional adult cystic fibrosis unit** *Oral Presenter*: Stephanie Graham, GB	14:00 - 14:00
P435	**Physical activity in young people with cystic fibrosis living in Latvia** *Oral Presenter*: Arta Ūdre, LV	14:00 - 14:00
P436	**Feasibility and effectiveness of a low-impact, virtual exercise programme for adults with cystic fibrosis** *Oral Presenter*: Ruth Watson, GB	14:00 - 14:00
P437	**Some do and some don't, but who will and who won't: can patterns of physical activity maintenance be predicted in children and young people with cystic fibrosis?** *Oral Presenter*: Helen Douglas, GB	14:00 - 14:00
P438	**Clinimetric properties of field exercise tests in cystic fibrosis: a systematic review** *Oral Presenter*: Jen Corda, AU	14:00 - 14:00
P439	**Feasibility of performing the three-minute step test with remote supervision in children and adolescents with cystic fibrosis** *Oral Presenter*: Marcio Vinicius Fagundes Donadio, BR	14:00 - 14:00
P440	**Can the 6-minute walking test assess physical activity level among people with cystic fibrosis?** *Oral Presenter*: Elpis Hatziagorou, GR	14:00 - 14:00
P441	**The A-Step – an incremental exercise test defying space and infection control measures** *Oral Presenter*: Natascha Remus, FR	14:00 - 14:00
P442	**Sleeping issues in children, adolescents and young adults** *Oral Presenter*: Lidija Skocir, SI	14:00 - 14:00
P443	**A sprint not a marathon: initial outcomes from a physiotherapist-led specialist cystic fibrosis (CF) Cardio-Pulmonary Exercise Testing (CPET) service for Wales** *Oral Presenter*: Rachel Young, GB	14:00 - 14:00
P444	**Self-perception of fitness levels vs CPET findings in adolescents with cystic fibrosis** *Oral Presenter*: Sioned Davies, GB	14:00 - 14:00
P445	**A marathon not a sprint: Establishing a physiotherapist led cystic fibrosis specific Cardio Pulmonary Exercise Testing (CPET) service for Wales** *Oral Presenter*: Rachel Young, GB	14:00 - 14:00
P446	**Physiotherapy input to cystic fibrosis screen positive indeterminate diagnosis patients at a regional paediatric cystic fibrosis unit** *Oral Presenter*: Nuala Harnett, GB	14:00 - 14:00
P447	**Effects of online core stabilisation exercises on posture in cystic fibrosis children** *Oral Presenter*: Kubra Kilic, TR	14:00 - 14:00

Industry Sessions
14:15 - 14:45 Tomorrow Lounge

MedTech Event

Special Symposium
15:00 - 16:30 R1

***SS01* - Best of Journal of Cystic Fibrosis, Lancet Respiratory Medicine and European Respiratory Journal**

Chair: Patrick Flume, US
Chair: Marcus Mall, DE
Chair: Emma Grainger, GB

	Introduction	15:00 - 15:05
	Journal of Cystic Fibrosis	15:05 - 15:25
	Estimating the Minimum Sample Size for Interventional and Observational Studies Using the Lung Clearance Index as an Endpoint *Speaker*: Felix Ratjen, CA *Discussant*: Sonya Heltshe, US	15:25 - 15:25
	Lancet Respiratory Medicine	15:25 - 15:45
	Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials *Speaker*: Alexander Horsley, GB *Discussant*: Felix Ratjen, CA	15:45 - 15:45
	European Respiratory Journal	15:45 - 16:05
	The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant *Speaker*: Pierre-Régis Burgel, FR *Discussant*: Peter Barry, GB	16:05 - 16:05
	Discussion – Hot Topics in Publishing	16:05 - 16:30

Workshop
15:00 - 16:30 R2

***WS01* - WS01 - Maximizing health: exploring novel strategies for exercise testing, physiotherapy, and musculoskeletal screening**

Chair: Marlies Wagner, AT
Chair: Emma Dixon, GB

WS01.01	**Cardiopulmonary exercise testing provides prognostic information in advanced cystic fibrosis lung disease** *Oral Presenter*: Thomas Radtke, CH	15:00 - 15:15
WS01.02	**The current state of play regarding exercise testing in cystic fibrosis: co-development with the community** *Oral Presenter*: Donald Urquhart, GB	15:15 - 15:30
WS01.03	**International Physiotherapy Group for Cystic Fibrosis (IPG/CF): international survey of physiotherapy practices in 2022 including airway clearance techniques, inhaled mucolytics and exercise**	15:30 - 15:45

Oral Presenter: Brenda Button, AU

WS01.04	**Longtime follow-up on exercise capacity and quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/iIvacaftor – a Copenhagen cohort** *Oral Presenter*: Lue Drasbæk Philipsen, DK	15:45 - 16:00
WS01.05	**Development of a musculoskeletal screening tool for children and young people with cystic fibrosis (Addenbrooke's MST): initial findings** *Oral Presenter*: Kieren James Lock, GB	16:00 - 16:15
WS01.06	**Inducing sputum in the adult cystic fibrosis post-modulator era** *Oral Presenter*: Alexander Williams, GB	16:15 - 16:30

Workshop
15:00 - 16:30 R3

WS02 **- WS02 - Fertility, pregnancy and gender-related topics**

Chair: Malena Cohen-Cymberknoh, IL
Chair: Quitterie Reynaud, FR

WS02.01	**Decreased fertility in female cystic fibrosis patients: peering into the endometrial factor using cutting-edge organoid models** *Oral Presenter*: Ellen De Pauw, BE	15:00 - 15:15
WS02.02	**Ovarian reserve in women with cystic fibrosis*:* is this a cause of subfertility?** *Oral Presenter*: Malena Cohen-Cymberknoh, IL	15:15 - 15:30
WS02.03	**Correlating menstrual cycles and cystic fibrosis symptoms among women with cystic fibrosis in the era of highly effective modulators: early findings of the MENSTRUAL study** *Oral Presenter*: Elinor Langfelder-Schwind, US	15:30 - 15:45
WS02.04	**Triple HEMT in Pregnancy and Lactation: effects on the developing lung, gut and pancreas** *Oral Presenter*: Elena Schneider-Futschik, AU	15:45 - 16:00
WS02.05	**Obstetric and neonatal outcomes in cystic fibrosis (CF) show minimal variability with and without elexacaftor/tezacaftor/ivacaftor (ETI)** *Oral Presenter*: Amy Downes, GB	16:00 - 16:15
WS02.06	**Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: MAYFLOWERS study interim results** *Oral Presenter*: Jennifer Taylor-Cousar, US	16:15 - 16:30

Workshop
15:00 - 16:30 R4

WS03 **- WS03 - Disease severity and survival: insight from registries**

Chair: Andreas Pfleger, AT
Chair: Elpis Hatziagorou, GR

WS03.01	**Differences in disease severity among different residual function mutations: data from the ECFS Patient Registry**	15:00 - 15:15

Oral Presenter: Meir Mei-Zahav, IL

WS03.02	**Keep your enemies close: natural foes, *Pseudomonas aeruginosa* and *Staphylococcus aureus* are associated with fewer adverse clinical consequences when present in patients with chronic co-infection** *Oral Presenter*: Micaela Mossop, GB	15:15 - 15:30
WS03.03	**Clinical outcomes and long-term survival in cystic fibrosis (CF) lung transplant recipients in Belgium** *Oral Presenter*: Muriel Thomas, BE	15:30 - 15:45
WS03.04	**Survival of people with cystic fibrosis: complete overview in France and first evaluation of the impact of modulators** *Oral Presenter*: Virginie Scotet, FR	15:45 - 16:00
WS03.05	**Multicenter validation of the cystic fibrosis-ABLE score as a predictor of outcome and therapeutic response in cystic fibrosis** *Oral Presenter*: Oliver James McElvaney, US	16:00 - 16:15
WS03.06	**Effective cystic fibrosis team training in low - and medium income countries leads to significant outcome improvements** *Oral Presenter*: Hector Gutierrez, US	16:15 - 16:30

Workshop
15:00 - 16:30 R5

***WS04* - WS04 - Understanding and correcting the CF cell: modulators and beyond**

Chair: Carlos M Farinha, PT
Chair: Carla Ribeiro, US

WS04.01	**A PI3Kγ mimetic peptide promotes F508del-CFTR plasma membrane stabilization through Protein Kinase D1** *Oral Presenter*: Alessandra Murabito, IT	15:00 - 15:15
WS04.02	**Impact of cholesterol on the functioning of CFTR modulators** *Oral Presenter*: Dorna Ravamehr-Lake, CA	15:15 - 15:30
WS04.03	**Elexacaftor/tezacaftor/ivacaftor (ETI) treatment corrects the salt-losing phenotype in people with cystic fibrosis (pwCF)** *Oral Presenter*: Peder Berg, DK	15:30 - 15:45
WS04.04	**CFTR modulator triple combination treatment modifies exhaled breath of children with cystic fibrosis within a week** *Oral Presenter*: Emmanuelle Bardin, FR	15:45 - 16:00
WS04.05	**Alternative targets for the treatment of cystic fibrosis basic defect** *Oral Presenter*: Floriana Guida, IT	16:00 - 16:15
WS04.06	**Validation of rectal organoid morphology analysis (ROMA) as a novel physiological CFTR assay for diagnosis of cystic fibrosis** *Speaker*: Senne Cuyx, BE	16:15 - 16:30

ECFS Tomorrow Lounge Session
15:00 - 16:00 Tomorrow Lounge

Dietetic management of the "well" person with CF

Chair: Fiona Moore, GB
Chair: Elizabeth Owen, GB

Workshop
17:00 - 18:30 R1

***WS05* - WS05 - Fresh results of clinical trials**

Chair: Damian Downey, GB
Chair: George Retsch-Bogart, US

WS05.01	**AAV mediated gene therapy for cystic fibrosis: interim results from a phase 1/2 clinical trial** *Oral Presenter*: Jennifer Taylor-Cousar, US	17:00 - 17:15
WS05.02	**A Phase-1 multiple ascending dose healthy volunteer study to evaluate the safety, tolerability, and pharmacokinetics of GDC-6988, a dry powder formulation of a selective inhaled potentiator of TMEM16A** *Oral Presenter*: Joshua Galanter, US	17:15 - 17:30
WS05.03	**A phase 3b study of the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on glucose tolerance in people with cystic fibrosis (CF) and abnormal glucose metabolism** *Oral Presenter*: Philip Robinson, AU	17:30 - 17:45
WS05.04	**Safety and efficacy of ivacaftor (IVA) in children aged 1 to <4 months with cystic fibrosis assessed with an innovative clinical trial design** *Oral Presenter*: Jane Davies, GB	17:45 - 18:00
WS05.05	**Randomised withdrawal of hypertonic saline in those with lower lung function after receiving elexacaftor/tezacaftor/ivacaftor; a sub-study of the SIMPLIFY Trial** *Oral Presenter*: Nicole Hamblett, US	18:00 - 18:15
WS05.06	**Phase 1/2a randomized, double-blind, placebo-controlled study: safety, Pk, and Efficacy outcome measures of inhaled Gallium Citrate (AR-501) in *P Aeruginosa* infected Cystic Fibrosis patients** *Oral Presenter*: Hasan Jafri, US	18:15 - 18:30

Workshop
17:00 - 18:30 R2

***WS06* - WS06 - Diagnostic tools for monitoring lung disease**

Chair: Florian Singer, AT
Chair: Felix Ratjen, CA

WS06.01	**Outcome measures for assessment of lung function – cross-sectional analysis of relationships between impulse oscillometry, electrical impedance tomography, multiple breath washout and spirometry** *Oral Presenter*: Gemma Stanford, GB	17:00 - 17:15
WS06.02	**How accurate is home spirometry? Comparison of home to office spirometry in the PROMISE study**	17:15 - 17:30

Oral Presenter: Margaret Rosenfeld, US

WS06.03	**A real-world evaluation of remote monitoring in cystic fibrosis care: a mixed-methods multicentre observational study** *Oral Presenter*: Marc C. Oppelaar, NL	17:30 - 17:45
WS06.04	**Lung volumes as possible factors explaining the heterogeneity in the response to elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease** *Oral Presenter*: Chiara Premuda, IT	17:45 - 18:00
WS06.05	**The volume of trapped air (VTA) from multiple breath washout (MBW) substantially underestimates the extent of trapped air (TA) demonstrated with spirometry-controlled computed tomography** *Oral Presenter*: Christopher Short, GB	18:00 - 18:15
WS06.06	**Effect of elexacaftor/tezacaftor/ivacaftor on structural lung damage after one year detected by magnetic resonance imaging** *Oral Presenter*: Samantha Conci, IT	18:15 - 18:30

Workshop
17:00 - 18:30 R3

***WS07* - WS07 - Pathogenesis and adaptation of microbes in the CF airways**

Chair: Lucas Hoffman, US
Chair: Dorothea Appelt, AT

WS07.01	**Inter-species interactions alter antimicrobial susceptibility in polymicrobial cultures** *Oral Presenter*: Eva Bernadett Benyei, GB	17:00 - 17:15
WS07.02	**Zebrafish infection model to assess persistence of *Pseudomonas aeruginosa* clinical isolates and treatment efficiency** *Oral Presenter*: Anne Blanc-Potard, FR	17:15 - 17:30
WS07.03	**A long-term study of *Pseudomonas aeruginosa* early patient isolate adaptation to the hypoxic environment** *Oral Presenter*: Joanna Drabinska, IE	17:30 - 17:45
WS07.04	**Hostile takeover factors of *Pseudomonas aeruginosa*: contact dependent secretion systems** *Oral Presenter*: Alice Christina Zammit Collins, GB	17:45 - 18:00
WS07.05	**Unraveling the pathogenicity of *Mycobacterium abscessus* clinical isolates in cystic fibrosis pulmonary epithelial cell and mouse models of respiratory infection** *Oral Presenter*: Nicola Ivan Lorè, IT	18:00 - 18:15
WS07.06	**CFTR impacts SARS-CoV-2 infection in cystic fibrosis** *Oral Presenter*: Cristina Cigana, IT	18:15 - 18:30

Workshop
17:00 - 18:30 R4

***WS08* - WS08 - Evaluating and treating gastrointestinal and liver diseases**

Chair: Helmut Ellemunter, AT
Chair: Michael Wilschanski, IL

WS08.01	**Evaluation of liver steatosis in people with cystic fibrosis using controlled attenuated parameter obtained by Fibroscan** *Oral Presenter*: Stephanie Van Biervliet, BE	17:00 - 17:15
WS08.02	**Change in hepatobiliary ultrasound measures, incl. shear wave elastography, after introduction of elexacaftor/tezacaftor/ivacaftor: results from 12-month follow-up in the Danish cystic fibrosis cohort** *Oral Presenter*: Christine Højte, DK	17:15 - 17:30
WS08.03	**Evaluating lung, liver and gut structure and function using MRI in 6 to 11 year olds – preliminary results from the GIFT-cystic fibrosis junior cohort** *Oral Presenter*: Alexander Yule, GB	17:30 - 17:45
WS08.04	**Faecal Immunochemical Testing – 'FIT' for purpose for bowel screening in older cystic fibrosis patients?** *Oral Presenter*: Karuna Sapru, GB	17:45 - 18:00
WS08.05	**Colorectal cancer-associated bacteria in adults with cystic fibrosis** *Oral Presenter*: Laura Caley, GB	18:00 - 18:15
WS08.06	**Pilot study evaluating the potential of *Akkermansia muciniphila* and *Faecalibacterium prausnitzii* as cystic fibrosis-specific probiotics utilising patient-derived organoid models** *Oral Presenter*: Keith Chee Y. Ooi, AU	18:15 - 18:30

Workshop
17:00 - 18:30 R5

***WS09* - WS09 - Genetics from different perspectives**

Chair: Milan Jr Macek, CZ
Chair: Margarida Amaral, PT

WS09.01	**Extending the success of Trikafta to rare mutations - insights from CFTR structure and modulator binding** *Oral Presenter*: Batsheva Kerem, IL	17:00 - 17:15
WS09.02	**Theratyping molecular defects of CFTR rare variants in patient derived rectal organoids** *Oral Presenter*: Anabela S. Ramalho, BE	17:15 - 17:30
WS09.03	**Delivery characterisation of SPL84 Inhaled Antisense Oligonucleotide** *Oral Presenter*: Gili Hart, IL	17:30 - 17:45
WS09.04	**Enhancement of channel activity of the CFTR protein delivered via gene therapy vectors**	17:45 - 18:00

Oral Presenter: Jim Hu, CA

WS09.05	**Aggregated genetic modifiers predict lung dysfunction at age 5-6 years in children with cystic fibrosis** *Oral Presenter*: Philip Farrell, US	18:00 - 18:15
WS09.06	**Genetic testing donors of gametes for cystic fibrosis should be mandatory** *Oral Presenter*: Guergana Petrova, BG	18:15 - 18:30

ECFS Tomorrow Lounge Session
17:00 - 18:00 Tomorrow Lounge

Psychosocial aspects of getting older with CF

Chair: Jacqueline Ali, GB
Chair: Sue Braun, BE

Friday, 09. June 2023

Industry Sessions
07:15 - 08:15 R5

Satellite Symposium

Meet the Experts
07:30 - 08:20

***MTE04* - Meet the Experts 04 - How better characterisation of CFTR gene variants has helped our patients; will extended gene sequencing be a help or a hindrance?**

Chair: Caroline Raynal, FR
Chair: Karen Raraigh, US

Meet the Experts
07:30 - 08:20

Meet the Experts

Meet the Experts
07:30 - 08:20

***MTE06* - Meet the Experts 06 - Post SIMPLIFY – what pulmonary therapies to rationalise and how to do it?**

Chair: Daniel Peckham, GB
Chair: Alex H. Gifford, US

Meet the Experts
07:30 - 08:20

***MTE05* - Meet the Experts 05 - Remote psychological counselling tools and strategies**

Chair: Marieke Verkleij, NL
Chair: Anna M. Georgiopoulos, US

Symposium
08:30 - 10:00 R1

***S11* - Symposium 11 - Are we ready for new clinical guidelines?**

Chair: Kevin Southern, GB
Chair: Isabelle Fajac, FR

What pathogens should we eradicate? 08:30 - 08:52
Speaker: Tavs Qvist, DK

Antibiotic strategies for exacerbation management 08:52 - 09:14
Speaker: Susanna Esposito, IT

How should we treat bronchopulmonary aspergillosis? 09:14 - 09:36
Speaker: Carsten Schwarz, DE

Are referral criteria for lung transplant different for people with CFTR modulators? 09:36 - 10:00
Speaker: Thomas Daniels, GB

Symposium
08:30 - 10:00 R2

***S12* - Symposium 12 - Essential nursing skills in the CFTR modulators era**

Chair: Tina D'Hondt, BE
Chair: Daniel Office, GB

Which treatments cannot be stopped and why - Supporting adherence in a healthier population 08:30 - 08:52
Speaker: Cora de Kiviet, NL

The impact of CFTR modulators on the liver, the gut and absorption 08:52 - 09:14
Speaker: Joanna Whitehouse, GB

Managing insulin and glycemic control after CFTR modulator initiation 09:14 - 09:36
Speaker: Espérie Burnet, FR
Speaker: Deborah Grunewald, FR

Life goes on – a patient perspective of their future aspirations and what they want from their cystic fibrosis team 09:36 - 10:00
Speaker: Katrien Van Gompel, BE

Symposium
08:30 - 10:00 R3

***S13* - Symposium 13 - Endocrinology and bone health in the era of CFTR modulators**

Chair: Monika Mielus, PL
Chair: Dimitri Declercq, BE

The abnormalities in glucose metabolism – how and when to treat? 08:30 - 08:52
Speaker: Amir Moheet, US

Oral glucose lowering agents - do we recommend them in cystic fibrosis? 08:52 - 09:14
Speaker: Amanda Brennan, GB

The effect of CFTR modulators on the endocrine system 09:14 - 09:36
Speaker: Laurence Kessler, FR

Consequences of CFTR modulators on bone health 09:36 - 10:00
Speaker: Susannah King, AU

Symposium
08:30 - 10:00 R4

***S14* - Symposium 14 - Assessment of *in vitro* biomarkers of CFTR function for prediction of clinical benefit**

Chair: David Sheppard, GB
Chair: Anabela Santo Ramalho, BE

Correlating CFTR function in cell lines with clinical features to inform personalised treatment of cystic fibrosis 08:30 - 08:52
Speaker: Garry Cutting, US

Using cystic fibrosis primary airway epithelial cells to predict lung function improvements by modulator therapies 08:52 - 09:14
Speaker: Isabelle Sermet-Gaudelus, FR

Comparison of organoid swelling and *in vivo* biomarkers of CFTR function to determine modulator effects 09:14 - 09:36

Speaker: Simon Graeber, DE

Can induced pluripotent stem cells be a feasible model for theratyping? 09:36 - 10:00

Speaker: Amy Wong, CA

Symposium
08:30 - 10:00 R5

***S15* - Symposium 15 - Pharmacovigilance in the real world: challenges and opportunities in an era of CFTR modulators**

Chair: Gwyneth Davies, GB
Chair: Meir Mei-Zahav, IL

PRO – We capture the right outcomes on CF Registries to support post-authorisation safety studies 08:30 - 08:48

Speaker: Lutz Naehrlich, DE

CON – We capture the right outcomes on CF Registries to support post-authorisation safety studies 08:48 - 09:06

Speaker: Jamie Duckers, GB

Discussion 09:06 - 09:16

Everybody matters – inclusive approaches to population-level analyses of the effectiveness of new therapies in cystic fibrosis 09:16 - 09:38

Speaker: Elizabeth Cromwell, US

Personalised medicine vs overmedicalisation in an era of CFTR modulators: insights from CF Registries 09:38 - 10:00

Speaker: Rita Padoan, IT

Symposium
10:30 - 12:00 R1

***S16* - Symposium 16 - CFTR modulators: opportunities and challenges**

Chair: Nicholas Simmonds, GB
Chair: Hettie Janssens, NL

Life-long CFTR modulation – is it sustained? 10:30 - 10:52

Speaker: Pierre-Régis Burgel, FR

Extra-pulmonary benefits of CFTR modulators 10:52 - 11:14

Speaker: Bradley Quon, CA

CFTR modulators: options for those who are intolerant 11:14 - 11:36

Speaker: Daniel Peckham, GB

CFTR modulators and neonates - how low should you go! 11:36 - 12:00

Speaker: Margaret Rosenfeld, US

Symposium
10:30 - 12:00 R2

***S17* - Symposium 17 - Masterclass in clinical CF – great cases**

Chair: Peter Barry, GB
Chair: Andreas Hector, CH

Mycobacterium abscessus in a young child with CF – the role of IFNg immune dysregulation 10:30 - 10:45

Speaker: Kushalinii Hillson, GB
Discussant: Andreas Hector, CH

After the honeymoon with CFTR-modulators, a rude awaikening with sudden and exceptionally severe infection. 10:45 - 11:00

Speaker: Tobias Schmidergall, DE
Discussant: Peter Barry, GB

Mind over modulator: A challenging case of mood disturbance in a young female following the introduction of Elexacaftor/Tezacaftor/Ivacaftor (ETI). 11:00 - 11:15

Speaker: Miriam Cameron, AU
Discussant: Barry Plant, IE

Pushing the limits in the era of CFTR modulators 11:15 - 11:30

Speaker: Georgia Mitropoulou, CH
Discussant: Lieven Dupont, BE

Altered sweat test: not only CFTR is involved. 11:30 - 11:45

Speaker: Joana Quaresma Vázquez, ES
Discussant: Silvia Gartner, ES

Increased breathless and reduced exercise tolerance in a Cystic Fibrosis patient undergoing a phase 3 randomized control trial. An unexpected and unrelated diagnosis 11:45 - 12:00

Speaker: Kevin Deasy, IE
Discussant: Ian Balfour-Lynn, GB

Symposium
10:30 - 12:00 R3

***S18* - Symposium 18 - Pregnancy and early parenthood for mums and dads with cystic fibrosis – it's a team effort!**

Chair: Jennifer Taylor-Cousar, US
Chair: David Kinoo, BE

Parenthood dilemmas - optimal medical and obstetric management strategies for pre/during and post CF pregnancy and early parenthood 10:30 - 10:52

Speaker: Imogen Felton, GB

Dinner for two (how to optimise nutrition pre/during/post pregnancy and early parenthood) 10:52 - 11:14

Speaker: Francis Hollander-Kraaijeveld, NL

Airway clearance and exercise – optimal physiotherapy interventions during pregnancy and early parenthood for mothers and fathers with cystic fibrosis 11:14 - 11:36

Speaker: Brenda Button, AU

Keeping the "me" in pregnancy (how to cope/support CF adults pre/during/post pregnancy and early parenthood) 11:36 - 12:00

Speaker: Trudy Havermans, BE

Symposium
10:30 - 12:00 R4

***S19* - Symposium 19 - Is there a future for phage therapy in cystic fibrosis?**

Chair: Oana Ciofu, DK
Chair: Gisli Einarsson, GB

Phage therapy to circumvent bacterial resistance in chronic infections 10:30 - 10:52
Speaker: Benjamin Chan, US

Combination therapy to fight bacterial infections: phages, antibiotics and immune adjuvants 10:52 - 11:14
Speaker: Anna Pistocchi, IT

Innovation in phage therapy: synergies, enzymes and engineered phages 11:14 - 11:36
Speaker: Maria del Mar Tomás Carmona, ES

Prediction of the success of phage therapy in the respiratory tract 11:36 - 12:00
Speaker: Oana Ciofu, DK

Symposium
10:30 - 12:00 R5

***S20* - Symposium 20 - Variation in the human genome is normal; get over it**

Chair: Halyna Makukh, UA
Chair: Emmanuelle Girodon, FR

M470V and other innocent CFTR variants; let them go 10:30 - 10:52
Speaker: Karen Raraigh, US

Using populations studies to better define the impact of CFTR variants such as T5 10:52 - 11:14
Speaker: Caroline Raynal, FR

The ever-expanding CFSPID tribe, where are they going? 11:14 - 11:36
Speaker: Tanja Gonska, CA

The psychological ramification of uncertain variants 11:36 - 12:00
Speaker: Paul Weldon, GB

Industry Sessions
12:30 - 14:00 R1

Satellite Symposium

ECFS Tomorrow Lounge Session
12:45 - 13:45

Research topics in CF nursing : how to get started

Chair: Espérie Burnet, FR
Chair: Malin Heiden, DK

ECFS Tomorrow Lounge Session
12:45 - 13:45 Tomorrow Lounge

Optimising weight management - a multidisciplinary discussion

Chair: Gemma Stanford, GB
Chair: Joanna Snowball, GB

ePoster Session
14:00 - 15:00 R2

***EPS05* - ePoster Session 5 - Gastrointestinal and nutritional changes upon CFTR modulators**

Chair: Chris Smith, GB
Chair: Keith Chee Y. Ooi, AU

EPS5.01	**Change in gut microbiota following elexacaftor/tezacaftor/ivacaftor (ETI) therapy: preliminary analysis** *Oral Presenter*: Laura Caley, GB	14:00 - 14:00
EPS5.02	**Faecal microbiota changes in patients with cystic fibrosis with 6 months of elexacaftor/tezacaftor/ivacaftor: preliminary findings from the PROMISE study** *Oral Presenter*: Jennifer T Duong, US	14:00 - 14:00
EPS5.03	**Elexacaftor / Tezacaftor / Ivacaftor for 76 weeks is associated with a reduced orocaecal transit time: the GIFT-CF3 extension study** *Oral Presenter*: Florence Lockwood, GB	14:00 - 14:00
EPS5.04	**Liver test abnormalities in adults with cystic fibrosis taking elexacaftor/tezacaftor/ivacaftor – one size doesn't fit all?** *Oral Presenter*: Daniel Tewkesbury, GB	14:00 - 14:00
EPS5.05	**Elexacaftor/tezacaftor/ivacaftor (ETI) - nutritional benefits are greatest for those in greatest need** *Oral Presenter*: Laura Kinsey, GB	14:00 - 14:00
EPS5.06	**Changes in body mass index, energy, fat and sodium intake with triple CFTR modulator therapy: preliminary analysis** *Oral Presenter*: Laura Caley, GB	14:00 - 14:00
EPS5.07	**Effect of elexacaftor/tezacaftor/ivacaftor on nutritional status in UK children with cystic fibrosis aged 6-11 years: a single centre service evaluation** *Oral Presenter*: Elizabeth Owen, GB	14:00 - 14:00
EPS5.08	**Elexacaftor/tezacafto/ ivacaftor reduces need for pancreatic enzymes, enteral feeding and omeprazole use without causing excessive weight gain: a 2-year observational study** *Oral Presenter*: Naomi Scanlan, GB	14:00 - 14:00
EPS5.09	**Changes in nutritional status and muscular strength in adult patients with cystic fibrosis (pwCF) treated with elexacaftor/tezacaftor/ivacaftor (ETI)** *Oral Presenter*: Cecilia Brignole, IT	14:00 - 14:00
EPS5.10	**Normonatremic salt depletion is not corrected in patients with cystic fibrosis treated with CFTR modulators** *Oral Presenter*: Gorana Levačić, HR	14:00 - 14:00

ePoster Session
14:00 - 15:00 R2

ePoster Session 5

ePoster Session
14:00 - 15:00 R3

ePoster Session 6

ePoster Session
14:00 - 15:00 R3

***EPS06* - ePoster Session 6 - Real world studies on elexacaftor/tezacaftor/ivacaftor**

Chair: Pavel Drevinek, CZ
Chair: Peter Barry, GB

EPS6.01	**Effects of elexacaftor/tezacaftor/ivacaftor therapy on sputum viscoelasticity, airway infection and inflammation in patients with cystic fibrosis** *Oral Presenter*: Laura Schaupp, DE	14:00 - 14:00
EPS6.02	**Elexacaftor/tezacaftor/ivacaftor results in substantial improvements in chest CT scores in people with cystic fibrosis aged 12 and above over one year of treatment** *Oral Presenter*: Paul McNally, IE	14:00 - 14:00
EPS6.03	**Pulmonary pathogen prevalence 12 months after elexacaftor/tezacaftor/ivacaftor introduction: results from the Danish National Cystic Fibrosis Cohort** *Oral Presenter*: Majbritt Jeppesen, DK	14:00 - 14:00
EPS6.04	**Elexacaftor/tezacaftor/ivacaftor (ETI) reduces sputum pathogen density and lung inflammation, butiInfection and inflammation persist** *Oral Presenter*: Samantha L Durfey, US	14:00 - 14:00
EPS6.05	**A phase 3b study of the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on cough and physical activity in people with cystic fibrosis (CF)** *Oral Presenter*: Eva Van Braeckel, BE	14:00 - 14:00
EPS6.06	**Impact of 6 months of treatment with elexacaftor/tezacaftor/ivacaftor on clinical outcomes in children aged 6-11 with cystic fibrosis – The RECOVER study** *Oral Presenter*: Paul McNally, IE	14:00 - 14:00
EPS6.07	**Longitudinal impact of elexacaftor/tezacaftor/ivacaftor on abdominal symptoms assessed with the CFAbd-Score and on intestinal inflammation in people with cystic fibrosis aged ≥ 12 years – The RECOVER study** *Oral Presenter*: Jochen Mainz, DE	14:00 - 14:00
EPS6.08	**Cystic fibrosis elexacaftor/tezacaftor/ivacaftor in liver or kidney transplanted people with cystic fibrosis using Tacrolimus, a drug-drug interaction study** *Oral Presenter*: Renske van der Meer, NL	14:00 - 14:00
EPS6.09	**Mid-term effect of elexacaftor/tezacaftor/ivacaftor on lung function in people with cystic fibrosis: real-world data of the German cystic fibrosis registry** *Oral Presenter*: Stefanie Dillenhöfer, DE	14:00 - 14:00
EPS6.10	**Evolution of psychic symptoms before and after 6 months of treatment with elexacaftor/tezacaftor/ivacaftor (ETI) in French adults patients with cystic fibrosis (pwCF)**	14:00 - 14:00

Oral Presenter: Quitterie Reynaud, FR

ePoster Session
14:00 - 15:00

***EPS07* - ePoster Session 7 - How much CF is it?**

Chair: Philippe Reix, FR

EPS7.01	**Cystic fibrosis screen positive inconclusive diagnosis (CFSPID): an Italian multicentre survey evaluating progression to definitive diagnoses** *Oral Presenter*: Cristina Fevola, IT	14:00 - 14:00
EPS7.02	**Cystic fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): A 15-year review**	14:00 - 14:00
EPS7.03	**Variability in evaluation and follow-up of newborns with CFSPID/CRMS In New York State Cystic Fibrosis Specialty Care Centres** *Oral Presenter*: Elinor Langfelder-Schwind, US	14:00 - 14:00
EPS7.04	**Evaluating CFSPID phenotypes and outcomes: a retrospective study from a large UK cystic fibrosis centre** *Oral Presenter*: Alison Mansfield, GB	14:00 - 14:00
EPS7.05	**The views of parents of children with Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID) on diagnosis, care and follow up** *Oral Presenter*: Sally Evans, GB	14:00 - 14:00
EPS7.06	**Hospital admissions due to pulmonary exacerbation in the first five years of life in children with cystic fibrosis in Ireland: the Irish Comparative Outcome Study of cystic fibrosis (ICOS)** *Oral Presenter*: Rini Bhatnagar, IE	14:00 - 14:00
EPS7.07	**Impact of newborn screening for cystic fibrosis – preliminary results from Norway** *Oral Presenter*: Magnhild Kolsgaard, NO	14:00 - 14:00

ePoster Session
14:00 - 15:00

ePoster Sessions 7 - 9

ePoster Session
14:00 - 15:00

***EPS08* - ePoster Session 8 - The vital role of physiotherapy in optimising airway clearance, lung function, and quality of life in the era of HEMTs**

Chair: David Kinoo, BE
Chair: Lisa Morrison, GB

EPS8.01	**Examining the evolution of physical activity in adults with cystic fibrosis and its relationship to lung function and maximal exercise capacity** *Oral Presenter*: Rachel Gyte, GB	14:00 - 14:00
EPS8.02	**Validation of the 25-level modified shuttle test in children with cystic fibrosis**	14:00 - 14:00

Oral Presenter: Jennifer Corda, AU

EPS8.03	**A pilot service conducting virtual induced sputum trials at the Blackpool Adult Cystic Fibrosis Service (BACFS)** *Oral Presenter*: Nicole Petch, GB	14:00 - 14:00
EPS8.04	**Effects of an high-intensity interval training or moderate-continuous intensity training on exercise capacity and body composition in people with cystic fibrosis – a randomized controlled study** *Oral Presenter*: Wolfgang Gruber, DE	14:00 - 14:00
EPS8.05	**One-minute sit-to-stand test improves with CFTR modulators** *Oral Presenter*: Morgane Penelle, BE	14:00 - 14:00
EPS8.06	**Prevalence of hypoglycaemia, measured by flash glucose monitoring, after moderate intensity aerobic exercise in adults with cystic fibrosis, compared to healthy controls** *Oral Presenter*: Tiffany Dwyer, AU	14:00 - 14:00
EPS8.07	**Relationship between circulating irisin levels with exercise capacity and muscle function in cystic fibrosis** *Oral Presenter*: Kubra Kilic, TR	14:00 - 14:00
EPS8.08	**Nintendo Switch ™ Ring Fit Adventure ™ as an alternative exercise option for people with cystic fibrosis during an inpatient admission: a pilot study of patient's perceptions** *Oral Presenter*: Nicole Petch, GB	14:00 - 14:00
EPS8.10	**Physiotherapy treatments used during pulmonary exacerbations requiring intensive therapy in Australia: data from the BEAT cystic fibrosis platform** *Oral Presenter*: Jamie Wood, US	14:00 - 14:00

ePoster Session
14:00 - 15:00

***EPS09* - ePoster Session 9 - Treatment of CF respiratory infection**

Chair: Michael Hogardt, DE
Chair: Laura Sherrard, GB

EPS9.01	**An *in vitro* model to predict the impact of CFTR functional restoration in the cystic fibrosis airway on *Pseudomonas aeruginosa* anti-microbial resistance, persistence and virulence** *Oral Presenter*: John King, GB	14:00 - 14:00
EPS9.02	**Pseudomonas aeruginosa in sputum cultures of patients with cystic fibrosis before and during one year of elexacaftor/tezacaftor/ivacaftor** *Oral Presenter*: Dorothea Appelt, AT	14:00 - 14:00
EPS9.03	**Long-term effects of Elexacaftor-Tezacaftor-Ivacaftor therapy on Cystic Fibrosis monocytes** *Oral Presenter*: Gloria Sangiorgi, IT	14:00 - 14:00
EPS9.04	**Changes in biofilm-tolerance of *Pseudomonas aeruginosa* to tobramycin following treatment with tobramycin inhalation powder (TIP)**	14:00 - 14:00

	Oral Presenter: Ross P. McCleave, GB	
EPS9.05	**Vantobra®, a new formulation of nebulised tobramycin: early real-world experiences at our large regional UK adult cystic fibrosis centre** *Oral Presenter*: Catherine Brown, GB	14:00 - 14:00
EPS9.06	**Development of levofloxacin resistance in clinical *Pseudomonas aeruginosa* isolates from people with cystic fibrosis in an *in vitro* variable exposure model** *Oral Presenter*: Callum Matthew Sloan, GB	14:00 - 14:00
EPS9.07	**Improving colistin activity against *Pseudomonas aeruginosa* biofilms** *Oral Presenter*: Valentina Pastore, IT	14:00 - 14:00
EPS9.08	**Antimicrobial photodynamic therapy with Ru(II)-loaded polymer nanocarriers towards treatment of bacterial lung infections: Proof-of-concept using cystic fibrosis *Pseudomonas aeruginosa* isolates** *Oral Presenter*: Mareike Müller, DE	14:00 - 14:00
EPS9.09	**Pilot study to evaluate the use of dry chlorine dioxide gas for sterilisation of virtual reality headsets** *Oral Presenter*: Victoria Daniel, GB	14:00 - 14:00
EPS9.10	**Could anti-*Pseudomonas aeruginosa* antibodies be a useful marker in monitoring the effect of ETI treatment on airways' microbiology in cystic fibrosis (CF)?** *Oral Presenter*: Daniela Dolce, IT	14:00 - 14:00

Poster Viewing
14:00 - 15:00

***PS2* - Poster Viewing 2**

P033	**Predictive biomarkers, and therapeutic targets, from the donor graft associated with the development of primary graft dysfunction after lung transplantation in cystic fibrosis patients** *Oral Presenter*: Emmanuelle Brochiero, CA	14:00 - 14:00
P035	**Partial correction of F508del-CFTR trafficking and stability defects by the combination of PTI-801 with ABBV-2222 or FDL-169** *Oral Presenter*: Miquéias Lopes-Pacheco, PT	14:00 - 14:00
P036	**A comparative study of cell culture inserts for *in vitro* modeling of the cystic fibrosis airway epithelium** *Oral Presenter*: Signe Lolle, DK	14:00 - 14:00
P037	**Home spirometry engagement in a paediatric network post pandemic** *Oral Presenter*: Philip Lawrence, GB	14:00 - 14:00
P102	**Clear illustration of improved survival in cystic fibrosis using the Kaplan-Meier method: the 50-year experience of Brittany, France** *Oral Presenter*: Virginie Scotet, FR	14:00 - 14:00
P103	**Ageing with cystic fibrosis – what can we expect?**	14:00 - 14:00

	Oral Presenter: Karuna Sapru, GB	
P105	**Epidemiological characteristics of children with cystic fibrosis in Bosnia and Herzegovina** *Oral Presenter*: Ganimeta Bakalovic, BA	14:00 - 14:00
P107	**DeltaF508 mutations, age of diagnosis and age of death for patients in Bulgaria** *Oral Presenter*: Guergana Petrova, BG	14:00 - 14:00
P108	**Demographic, clinical and laboratory characteristics in cystic fibrosis population from Republic of Moldova** *Oral Presenter*: Oxana Turcu, MD	14:00 - 14:00
P109	**Real-life efficacy of elexacaftor/tezacaftor/ivacaftor in the Dutch cystic fibrosis population** *Oral Presenter*: Domenique Zomer-van Ommen, NL	14:00 - 14:00
P110	**Change in sweat chloride concentration after elexacaftor/tezacaftor/ivacaftor initiation: results from 12 months follow-up in the Danish cystic fibrosis cohort** *Oral Presenter*: Thomas Bryrup, DK	14:00 - 14:00
P111	**Forced oscillation techniques – is it useful for the monitoring adult patients with cystic fibrosis in the era of CFTR modulators** *Oral Presenter*: Andrea Vukić Dugac, HR	14:00 - 14:00
P112	**Variation in eligibility to highly effective modulator therapy between ethnic groups at our centre and how this is reflected in median lung function** *Oral Presenter*: Malithi Fernando, GB	14:00 - 14:00
P113	**Home reported outcomes (HERO-2) in people with cystic fibrosis taking elexacaftor/tezacaftor/ivacaftor: self-reported changes in use of chronic daily therapies at enrollment** *Oral Presenter*: Cynthia Brown, US	14:00 - 14:00
P114	**Predicting poor responses to elexacaftor/tezacaftor/ivacaftor: are all responses created equal?** *Oral Presenter*: Matthew Craggs, GB	14:00 - 14:00
P115	**The RISE study protocol: Resilience lmpacted by positive Stressful Events for people with cystic fibrosis** *Oral Presenter*: Sabine Elena Ineke van der Laan, NL	14:00 - 14:00
P116	**Elexacaftor/tezacaftor/ivacaftor during pregnancy: the effect on maternal ppFEV$_1$** *Oral Presenter*: Nina Broen Jakobsen, DK	14:00 - 14:00
P117	**A longitudinal study on the impact of elexacaftor/tezacaftor/ivacaftor treatment on quality of life in people with cystic fibrosis in the real world** *Oral Presenter*: Sivagurunathan Sutharsan, DE	14:00 - 14:00
P118	**Real-world impact of elexacaftor/tezacaftor/ivacaftor on quality of life of children with cystic fibrosis aged 6-11 years and primary caregivers in the UK: MAGNIFY, a prospective, observational, non-interventional study**	14:00 - 14:00

	Oral Presenter: Lena P. Thia, GB	
P119	**Exploring the attitudes and knowledge of the caregivers of children with cystic fibrosis and primary ciliary dyskinesia regarding COVID-19 vaccination** *Oral Presenter*: Seyda Karabulut, TR	14:00 - 14:00
P120	**Adherence to elexacaftor/texacaftor/ivacaftor during the first 2 years of treatment in an adolescent population** *Oral Presenter*: Amanda Bevan, GB	14:00 - 14:00
P121	**Vaccine coverage in people with cystic fibrosis** *Oral Presenter*: Lior Tsviban, IL	14:00 - 14:00
P122	**Immunization coverage and new issues of it at the age of novel CFTR modulator therapies in adults with cystic fibrosis** *Oral Presenter*: Macha Tetart, FR	14:00 - 14:00
P123	**Survey on medication-taking habits among patients with cystic fibrosis in a state of Argentina: a cross-sectional study** *Oral Presenter*: Ezequiel Baran, AR	14:00 - 14:00
P124	**Vaccination situation against COVID-19 in an adults cystic fibrosis center in Argentina** *Oral Presenter*: Ezequiel Baran, AR	14:00 - 14:00
P125	**Long-term economic impact using a virtual model of care in cystic fibrosis** *Oral Presenter*: Paola Iacotucci, IT	14:00 - 14:00
P126	**Health care resource use (HCRU) and associated costs preceding lung transplantation (LT) in Cystic Fibrosis patients** *Oral Presenter*: Isabelle Durieu, FR	14:00 - 14:00
P127	**Twenty years and counting: longitudinal trends in real-world primary outcomes for people with cystic fibrosis in Ireland and the evolution of a registry** *Oral Presenter*: Laura Kirwan, IE	14:00 - 14:00
P128	**Successful deployment of a cystic fibrosis registry solution in a low-and-middle-income country – a pilot** *Oral Presenter*: Hector Gutierrez, US	14:00 - 14:00
P129	**The cystic fibrosis epidemiology changing in Ukraine due to war in 2022-2023** *Oral Presenter*: Halyna Makukh, UA	14:00 - 14:00
P130	**Exploring consequences of highly effective modulator therapy on patient's health pathways and cares in cystic fibrosis centers and beyond by a nationwide research programme in France (HORIZON)** *Oral Presenter*: Philippe Reix, FR	14:00 - 14:00
P131	**Investigation of healthcare-associated links in transmission of nontuberculous mycobacteria (HALT NTM)** *Oral Presenter*: Jane E. Gross, US	14:00 - 14:00
P132	**Clinical outcomes are comparable between shared care and**	14:00 - 14:00

	centralised care *Oral Presenter*: Anders Lindblad, SE	
P133	**Cystic fibrosis in two countries located in Northern and Eastern Europe: problems and perspectives** *Oral Presenter*: Nataliya Rohovyk, SE	14:00 - 14:00
P134	**Evaluation of multidisciplinary ambulatory care cost among children with cystic fibrosis: a comparative study between cystic fibrosis centers in Ireland and the United States** *Oral Presenter*: Ryan Perkins, US	14:00 - 14:00
P135	**Demographics profile and societal burden among persons with cystic fibrosis in the Danish population 1990 to 2018** *Oral Presenter*: Camilla Bjørn Jensen, DK	14:00 - 14:00
P136	**ECFS syllabuses for the multidisciplinary team and wider field: a guide for comprehensive education** *Oral Presenter*: Chris Smith, GB	14:00 - 14:00
P137	**Assessment of the quality of data in the European Cystic Fibrosis Society Patient Registry** *Oral Presenter*: Vibha Prasad, DE	14:00 - 14:00
P138	**The impact of cystic fibrosis on periodontal disease and oral hygiene levels in adults: results from a clinical study** *Oral Presenter*: Niamh Coffey, IE	14:00 - 14:00
P139	**Scandinavian cystic fibrosis registry study - comparing care and clinical outcome** *Oral Presenter*: Anita C. Senstad Wathne, NO	14:00 - 14:00
P140	**Characterization of sleep in emerging adults with cystic fibrosis on highly effective modulator therapy** *Oral Presenter*: Jane E. Gross, US	14:00 - 14:00
P141	**Microbiological evaluation of an automated UV-disinfection robot on cystic fibrosis-related pathogens** *Oral Presenter*: Kim Thomsen, DK	14:00 - 14:00
P142	**Review of diagnostic labels for patients with unconfirmed cystic fibrosis diagnosis using registry data** *Oral Presenter*: Simeon Situma Wanyama, BE	14:00 - 14:00
P143	**The promise of emulating trials using registry data with an illustrative example: the effect of azithromycin on lung function** *Oral Presenter*: Emily Granger, GB	14:00 - 14:00
P144	**Self-medication and use of complementary and alternative medicines in cystic fibrosis – MUCAUTOMED study** *Oral Presenter*: Sophie Lemagner, FR	14:00 - 14:00
P145	**Cystic fibrosis in Iceland** *Oral Presenter*: Helga Elídóttir, SE	14:00 - 14:00
P146	**COVID-19 pandemic in the Belgian cystic fibrosis patients compared with the international cystic fibrosis patients and the general Belgian population** *Oral Presenter*: Géraldine Daneau, BE	14:00 - 14:00

P147	**“What options are available for those not able to take current CFTR modulators?”: an answer hidden in plain sight?** *Oral Presenter*: Tracey Daniels, GB	14:00 - 14:00
P150	**Arthropathy in cystic fibrosis (protocol abstract)** *Oral Presenter*: Anne Sofie Rosenborg Peretz, DK	14:00 - 14:00
P151	**Pregnancies with elexacaftor/tezacaftor/ivacaftor in Argentina** *Oral Presenter*: Ezequiel Baran, AR	14:00 - 14:00
P152	**Development and validation of a personalised electronic patient-reported outcome measure to assess individual quality of life** *Oral Presenter*: Danya Muilwijk, NL	14:00 - 14:00
P153	**An Italian centre experience with elexacaftor/tezacaftor/ivacaftor therapy in 6 to 11 year olds with cystic fibrosis** *Oral Presenter*: Chiara Rosazza, IT	14:00 - 14:00
P154	**Cluster analysis explains heterogeneity in treatment response to elexacaftor/tezacator/ivacaftor in people with cystic fibrosis** *Oral Presenter*: Chiara Premuda, IT	14:00 - 14:00
P155	**The impact of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on occurrence of bacterial lung infections in cystic fibrosis patients** *Oral Presenter*: Maria Francesca Liporace, IT	14:00 - 14:00
P156	**Treatment with the CFTR modulator [HB1] elexacafor/tezacaftor/ivacaftor reduces immunological response to airway *Aspergillus* in people with cystic fibrosis** *Oral Presenter*: Natalie Francis, GB	14:00 - 14:00
P157	**Severe cystic fibrosis in the CFTR modulator era still exists! The implementation of a novel ‘high risk’ multidisciplinary team approach** *Oral Presenter*: Thomas Tobin, GB	14:00 - 14:00
P158	**Elexacaftor, tezacaftor, Ivacaftor (ETI) improves lung function but not rate of decline in a two year observational study of adolescents** *Oral Presenter*: Garry Connett, GB	14:00 - 14:00
P159	**Modulator`s effectiveness evaluated by lung ultrasound** *Oral Presenter*: Ioana Mihaela Ciuca, RO	14:00 - 14:00
P160	**Effects of elexacaftor/tezacaftor/ivacaftor triple combination therapy on glycaemic control and body composition in patients with cysticfibrosis related diabetes** *Oral Presenter*: Laura Zazzeron, IT	14:00 - 14:00
P161	**Desensitization to highly effective modulator therapy – international approach and call for collaboration**	14:00 - 14:00

Oral Presenter: Elizabeth Autry, US

P162	**Elexacaftor/tezacaftor/ivacaftor significantly improves thoracic radiological outcomes in cystic fibrosis** *Oral Presenter*: Nicola Robinson, GB	14:00 - 14:00
P163	**Impact of elexacaftor/tezacaftor/ivacaftor modulator therapy on cystic fibrosis chest radiographs using the Brasfield score, a single centre experience** *Oral Presenter*: Mohammed Okour, GB	14:00 - 14:00
P164	**Elexacaftor/tezacaftor/ivacaftor (ETI)– home spirometry during the first 14 days of treatment** *Oral Presenter*: Matthieu Thimmesch, BE	14:00 - 14:00
P165	**Impact of CFTR modulators on systemic inflammation** *Oral Presenter*: Ivan Bambir, HR	14:00 - 14:00
P166	**Losses in the gains of children with cystic fibrosis who had to interrupt their modulator therapies** *Oral Presenter*: Burcu Capraz, TR	14:00 - 14:00
P167	**Antibiotic courses in children and adolescents with cystic fibrosis: after only a year of elexacaftor/tezacaftoriIvacaftor, there's a "before and after"** *Oral Presenter*: Joana Quaresma Vázquez, ES	14:00 - 14:00
P168	**Determining the relationship between vitality and C-Reactive protein in those initiating elexacaftor/tezacaftor/ivacaftor** *Oral Presenter*: Jacob Gravelle, CA	14:00 - 14:00
P169	**Vitamin absorption after the introduction of elexacaftor/tezacaftor/ivacaftor in children and adolescents diagnosed with cystic fibrosis** *Oral Presenter*: Ana Morales Tirado, ES	14:00 - 14:00
P170	**Trikafta® modulates release of extracellular vesicles in cystic fibrosis** *Oral Presenter*: navya lakkappa, IE	14:00 - 14:00
P171	**Clinical experience with the introduction of a programme with CFTR modulators in a paediatric cystic fibrosis centre in Poland - a preliminary report** *Oral Presenter*: Katarzyna Walicka-Serzysko,	14:00 - 14:00
P172	**CFTR Modulators in children with cystic fibrosis: real-life evidence in Turkey** *Oral Presenter*: Ismail Guzelkas, TR	14:00 - 14:00
P173	**Modulatory therapy experience in patients with cystic fibrosis in Turkey: a multi-centre study** *Oral Presenter*: Aynur Gulieva, TR	14:00 - 14:00
P174	**Human epididymis protein 4 (HE4) plasma concentrations**	14:00 - 14:00

	correlate with the improvement of ppFEV1 in response to LUM/IVA therapy in people with cystic fibrosis homozygous for p.Phe508del-CFTR *Oral Presenter*: Marianna Pócsi, HU	
P175	**Changes in breathprint after start of tezacaftor/ivacaftor therapy: an eNose pilot study** *Oral Presenter*: Alain P. Iradukunda, NL	14:00 - 14:00
P176	**Implantable venous access devices in the era of Trikafta®– time for a rethink?** *Oral Presenter*: Sheila Sivam, AU	14:00 - 14:00
P177	**Cystic fibrosis (CF)-related complications and outcomes of women during pregnancy and post-partum in elexacaftor/tezacaftor/ivacaftor (ETI)-era** *Oral Presenter*: Amy Downes, GB	14:00 - 14:00
P178	**Impact of pre-conception lung function in women with cystic fibrosis (wwCF) on obstetric and neonatal outcomes in the elexacaftor/tezacaftor/ivacaftor (ETI)-era** *Oral Presenter*: Amy Downes, GB	14:00 - 14:00
P179	**Maternal and foetal outcomes of multigravida cystic fibrosis patients** *Oral Presenter*: Malena Cohen-Cymberknoh, IL	14:00 - 14:00
P180	**Evaluation of clinical features of children with cystic fibrosis and CFSPID in newborn screening programme with IRT/IRT protocol** *Oral Presenter*: Tugba Sismanlar Eyuboglu, TR	14:00 - 14:00
P181	**Polygenic risk score and socioenvironmental factors predict early-onset lung disease in young children with cystic fibrosis** *Oral Presenter*: Leslie Huang, US	14:00 - 14:00
P182	**Prevalence of tracheobronchomalacia is higher than previously reported in children with cystic fibrosis** *Oral Presenter*: Julie Depiazzi, AU	14:00 - 14:00
P184	**Sex differences in annual pulmonary exacerbations in people with cystic fibrosis** *Oral Presenter*: Kristina Montemayor, US	14:00 - 14:00
P185	**Prospective randomized observational study validating biomarkers for association with future pulmonary exacerbations in people with cystic fibrosis** *Oral Presenter*: Theodore G Liou, US	14:00 - 14:00
P186	**Airway clearance in the STOP PEDS pilot study of oral antibiotic treatment strategies for paediatric cystic fibrosis pulmonary exacerbations** *Oral Presenter*: Don Sanders, US	14:00 - 14:00
P187	**Small airways disease in cystic fibrosis patients** *Oral Presenter*: Michela Deolmi, IT	14:00 - 14:00
P188	**Heterogeneity of large and small airway remodeling in human end-stage explant cystic fibrosis lungs**	14:00 - 14:00

	Oral Presenter: Astrid Vermaut, BE	
P190	**Nanostructured formulation of a novel hybrid iminosugar/steroid agent for application in cystic fibrosis lung disease** *Oral Presenter*: Anna Esposito, IT	14:00 - 14:00
P191	**Is abnormal glucose tolerance driving lung inflammation in cystic fibrosis?** *Oral Presenter*: Stefanie Diemer, SE	14:00 - 14:00
P192	**Change in lung clearance index with microbiological status in patients with cystic fibrosis** *Oral Presenter*: Elpis Hatziagorou, GR	14:00 - 14:00
P193	**Lung clearance index in asymptomatic CRMS/CFSPID infants progressed to a diagnosis of cystic fibrosis for pathological sweat test: a monocentric prospective experience** *Oral Presenter*: Cristina Fevola, IT	14:00 - 14:00
P194	**Computed cardiopulmonography (CCP) and the idealised lung clearance index (iLCI) in early-stage cystic fibrosis** *Oral Presenter*: Christopher Short, GB	14:00 - 14:00
P195	**Prospective longitudinal evaluation of the lung clearance index (LCI) in the clinical setting** *Oral Presenter*: Jacqueline Spano, US	14:00 - 14:00
P196	**Use of nose clips for routine spirometry helps maximise forced expiratory outcome measures in cystic fibrosis clinics** *Oral Presenter*: Garry Connett, GB	14:00 - 14:00
P197	**A pilot study to determine whether normative values of specialised pulmonary function tests differ in children from non-Caucasian, ethnic minority backgrounds** *Oral Presenter*: Mary Abkir, GB	14:00 - 14:00
P198	**Home spirometry as a clinical trial endpoint: qualitative needs assessment and co-production of training materials** *Oral Presenter*: Margaret Rosenfeld, US	14:00 - 14:00
P199	**Non-invasive monitoring of cystic fibrosis lung disease in a new era: the TERRIFIC-MILE study** *Oral Presenter*: Hettie Janssens, NL	14:00 - 14:00
P207	**CFHealthHub allows clinicians to identify people with long nebuliser durations and intervene to reduce duration** *Oral Presenter*: Robert D Sandler, GB	14:00 - 14:00
P209	**Personalised data-Linkage Understanding Treatment Optimisation (PLUTO) in the CFHealthHub Learning Health System: understanding how much is enough for normal life expectancy in the post-modulator era** *Oral Presenter*: Robert D Sandler, GB	14:00 - 14:00
P210	**Environmental impact of a cystic fibrosis virtual clinic** *Oral Presenter*: David Green, GB	14:00 - 14:00
P211	**The impact of multidisciplinary virtual cystic fibrosis clinics**	14:00 - 14:00

	on patient experience, quality of life, costs and time commitments *Oral Presenter*: Jody Bell, AU	
P212	**Clinical and transcriptomic features of COVID-19 in cystic fibrosis: a prospective multi-centre study** *Oral Presenter*: Fabiana Ciciriello, IT	14:00 - 14:00
P214	**Clinical course of SARS-CoV-2 infections of paediatric patients with cystic fibrosis– a single retrospective centre experience** *Oral Presenter*: Justyna Sieber, AT	14:00 - 14:00
P215	**Intravenous antibiotic administration in children and adolescents with cystic fibrosis and catheter-associated complications: a 5-year experience** *Oral Presenter*: Mónica López Rozas, ES	14:00 - 14:00
P216	**The impact of the COVID-19 pandemic and elexacaftor/tezacaftor/ivacaftor initiation on high-cost medication utilisation in adults living with cystic fibrosis** *Oral Presenter*: Alex Chan, GB	14:00 - 14:00
P217	**Arthritis in cystic fibrosis – case series and review** *Oral Presenter*: Anne Sofie Rosenborg Peretz, DK	14:00 - 14:00
P219	**Otorhinolaryngologic, audiological and genetic findings in children with cystic fibrosis: a tertiary care experience** *Oral Presenter*: Raziye Atan, TR	14:00 - 14:00
P220	**The CFHealthHub Learning Health System - supporting a community of practice to deliver a normal life expectancy in cystic fibrosis** *Oral Presenter*: Robert D Sandler, GB	14:00 - 14:00
P221	**Identifying knowledge gaps by using adapted cystic fibrosis R.I.S.E. in a low-resource setting** *Oral Presenter*: Seyda Karabulut, TR	14:00 - 14:00
P222	**Multi-central profile of refugee cystic fibrosis patients in Turkey**	14:00 - 14:00
P223	**Transition programme as a quality improvement project: adaptation of the R.I.S.E. in a centre with limited resources – Marmara University experience** *Oral Presenter*: Seyda Karabulut, TR	14:00 - 14:00
P224	**Eligibility of CFTR Modulator [HB1] drugs in patients registered in cystic fibrosis registry of Turkey** *Oral Presenter*: Meltem Akgül Erdal, TR	14:00 - 14:00
P226	**Interpretation of spirometry parameters in adult patients with cystic fibrosis in North Macedonia** *Oral Presenter*: Sonja Momchilovikj,	14:00 - 14:00
P345	**The clinical impact of reduced dose prescribing of**	14:00 - 14:00

	elexacaftor/tezaxaftor/ivacaftor (ETI) in children with cystic fibrosis *Oral Presenter*: Amanda Thomsen, AU	
P346	**The Alfred Wellness Score (AWESCORE©): measurements of quality of life before and after the introduction of elexacaftor/tezacaftor/ivacaftor (Trikafta®) in adults with cystic fibrosis** *Oral Presenter*: Brenda Button, AU	14:00 - 14:00
P347	**Mental health after initiating triple CFTR modulators in a Polish paediatric cystic fibrosis centre - a preliminary report** *Oral Presenter*: Urszula Borawska-Kowalczyk, PL	14:00 - 14:00
P348	**The impact of CFTR modulators on the quality of life of adult patients with cystic fibrosis in Croatia** *Oral Presenter*: Tihana Odobasic Palkovic,	14:00 - 14:00
P349	**Body image perceptions and elexacaftor/tezacaftor/ivacaftor (ETI) use in adolescents living with cystic fibrosis in the United States** *Oral Presenter*: Emily Muther, US	14:00 - 14:00
P350	**Impact of one year of treatment with elexacaftor/tezacaftor/ivacaftor on clinical outcomes in adult patients with cystic fibrosis - first experience from Croatia** *Oral Presenter*: Ivana Lalić Čičković, HR	14:00 - 14:00
P351	**Adherence to chronic treatment by adult patients with cystic fibrosis in the era of CFTR modulators** *Oral Presenter*: Ivana Lalić Čičković, HR	14:00 - 14:00
P352	**New therapy, new adherence idea?** *Oral Presenter*: Paola Catastini, IT	14:00 - 14:00
P353	**Impact of the withdrawal of CFTR modulator prescriptions on clinic attendance** *Oral Presenter*: Michael Kevin Dooney, GB	14:00 - 14:00
P354	**West Midlands Adult Cystic Fibrosis Centre experience of the effects of Kaftrio® on patients within the lung transplant programme** *Oral Presenter*: Josephine Hussey, GB	14:00 - 14:00
P355	**A qualitative study exploring parent's experience of the diagnosis of cystic fibrosis for their newborn baby** *Oral Presenter*: Mark Guyers, GB	14:00 - 14:00

P356	**A qualitative study on awareness, attitudes, behaviors and social adaptation of mothers of children with cystic fibrosis** *Oral Presenter*: İlknur Ayvaz, TR	14:00 - 14:00
P357	**Psychological study of the relationship between pain perception and fear, anxiety and quality of life in children with cystic fibrosis** *Oral Presenter*: Géraldine Labouret, FR	14:00 - 14:00
P358	**Anxiety and depression levels reported by parents of children with cystic fibrosis over a 6-month period** *Oral Presenter*: Claire Edmondson, GB	14:00 - 14:00
P359	**“No words for feelings” The factors effecting alexithymia in the patients with cystic fibrosis and their mothers** *Oral Presenter*: Ayse Tana Aslan, TR	14:00 - 14:00
P360	**Mental health in cystic fibrosis patients: predictive factors and psychopathology** *Oral Presenter*: Carlo Castellani, IT	14:00 - 14:00
P361	**Psychological and physical impact of coughing in patients with cystic fibrosis (CF)** *Oral Presenter*: Ivana Arnaudova Danevska,	14:00 - 14:00
P362	**Employment and life choices for PwCF in Wales – 10 years on** *Oral Presenter*: Vivien S. Edwards, GB	14:00 - 14:00
P363	**Socio-economic choices in the cystic fibrosis family with a child with cystic fibrosis in primary school** *Oral Presenter*: Karin Risager Jakobsen, DK	14:00 - 14:00
P364	**Financial and logical impacts of review appointments on parents of children with cystic fibrosis** *Oral Presenter*: Anirban Maitra, GB	14:00 - 14:00
P365	**‘Shouldn’t you be thinking about work now?’- employment status and influencing clinical factors in people with cystic fibrosis at a large UK adult centre** *Oral Presenter*: Jacqui Wainwright, GB	14:00 - 14:00
P366	**Developing an in-house and integrated sweat testing service for the routine management of adults with cystic fibrosis** *Oral Presenter*: Lindsey Gillgrass, GB	14:00 - 14:00
P367	**Antibiotic treatment of *Staphylococcus* aureus in small children with newly diagnosed cystic fibrosis - a nursing care experience in the Nordic countries** *Oral Presenter*: Ellen Julie Hunstad, NO	14:00 - 14:00
P368	**Antibiotic prescribing practice of the cystic fibrosis (CF) nursing team at a large tertiary paediatric centre** *Oral Presenter*: Lauren Bartlett, GB	14:00 - 14:00
P369	**Electronic prescribing: A service improvement project** *Oral Presenter*: Claire Fagan, GB	14:00 - 14:00
P370	**Exploring the barriers and facilitators to obtaining supplies of medicines for people with cystic fibrosis (PwCF) under**	14:00 - 14:00

	the care of the All Wales Adult Cystic Fibrosis Centre (AWACFC) *Oral Presenter*: Mari Lea-Davies, GB	
P371	**Art therapy to facilitate interaction among children with cystic fibrosis** *Oral Presenter*: Claire Fagan, GB	14:00 - 14:00
P372	**"The outcome would not have been the same" - multidisciplinary team experience of the role of occupational therapy in a Cystic Fibrosis unit** *Oral Presenter*: Wendy Foo, GB	14:00 - 14:00
P373	**Teamwork makes the dream work: joint working between social work and occupational therapy in adult cystic fibrosis care** *Oral Presenter*: Wendy Foo, GB	14:00 - 14:00
P374	**The role of a specialist youth worker in cystic fibrosis care in Wales** *Oral Presenter*: Bethan Watkins, GB	14:00 - 14:00
P375	**Brighter Futures with Study Buddies: an educational programme, delivered by the cystic fibrosis-MDT of tomorrow, to enable improved health literacy and essential skills for life and employability in the young PwCF** *Oral Presenter*: Jacqueline Rendall, GB	14:00 - 14:00
P376	**Co-developing health and lifestyle education for adolescents with cystic fibrosis** *Oral Presenter*: Sally Ann Harris, GB	14:00 - 14:00
P377	**Addressing the many steps to a successful transition!** *Oral Presenter*: Karoline Prinz, AT	14:00 - 14:00
P378	**The value of a community of practice, within the CFHealthHub learning health system** *Oral Presenter*: Tracey Daniels, GB	14:00 - 14:00
P379	**Impact of a mental health navigator for cystic fibrosis care in British Columbia** *Oral Presenter*: Callie Waters, CA	14:00 - 14:00
P380	**One stop annual review process** *Oral Presenter*: Katie Baker-Wardle, GB	14:00 - 14:00
P382	**Cystic fibrosis and disordered eating behaviour: a collaborative approach to improve care** *Oral Presenter*: Rachel Massey-Chase, GB	14:00 - 14:00
P383	**"It was all tailored around me": qualitative evaluation of Clinical Effort Against Smoke Exposure in cystic fibrosis (CEASE-CF)** *Oral Presenter*: Gabriela Oates, US	14:00 - 14:00
P384	**Smoking prevalence in cystic fibrosis families is higher than in the Greek general population** *Oral Presenter*: Argyri Petrocheilou, GR	14:00 - 14:00
P385	**Measuring what matters to patients**	14:00 - 14:00

	Oral Presenter: Martina Kapatou, GB	
P386	**Improving support for sexual and reproductive health in adult patients with cystic fibrosis** *Oral Presenter*: Elizabeth C Benson, GB	14:00 - 14:00
P387	**Reviews and outcomes from a new pregnancy support service at a large cystic fibrosis centre** *Oral Presenter*: Beverly Govin, GB	14:00 - 14:00
P388	**Three new mums, 1 big realisation: a maternity leave reflection on cystic fibrosis care postpartum** *Oral Presenter*: Lucy Wadsworth, GB	14:00 - 14:00
P389	**Evolving gender identification within the cystic fibrosis population and considerations on potential effects on lung function results** *Oral Presenter*: Alice Darby, GB	14:00 - 14:00
P390	**Ageing with cystic fibrosis: challenges for patients and team members** *Oral Presenter*: Sue Braun, BE	14:00 - 14:00
P391	**“I’m different”: reviewing outpatient psychology support for people of colour in an inner London adult cystic fibrosis centre** *Oral Presenter*: Ghiselle Green, GB	14:00 - 14:00
P392	**Medical and mental status of refugees with cystic fibrosis from Ukraine** *Oral Presenter*: Carsten Schwarz, DE	14:00 - 14:00
P393	**Physical activity participation and mental health status of patients with cystic fibrosis during the COVID-19 pandemic: a single centre experience** *Oral Presenter*: Silvia Delgado, US	14:00 - 14:00
P394	**Comparisons of the personal well-being score (PWS) and health-related quality of life for people with cystic fibrosis before and during the COVID-19 pandemic** *Oral Presenter*: Rana Altabee, GB	14:00 - 14:00
P395	**Completeness of annual review investigations as per national recommendations after the COVID-19 pandemic – experience from a large tertiary centre in the northwest United Kingdom** *Oral Presenter*: Anirban Maitra, GB	14:00 - 14:00
P396	**Moral distress and burnout in healthcare workers during the COVID-19 pandemic: quantitative results from a large Australian public hospital survey** *Oral Presenter*: Felicity Finlayson, AU	14:00 - 14:00
P397	**Using the science of health care improvement to implement a virtual cystic fibrosis clinic alongside the traditional face-to-face model post-COVID pandemic** *Oral Presenter*: Julie Knowles, GB	14:00 - 14:00
P398	**Using the science of health care improvement to implement a virtual cystic fibrosis service post COVID-19 pandemic**	14:00 - 14:00

Oral Presenter: Julie Knowles, GB

P399 **Using a digital learning health system to reduce medicines waste in cystic fibrosis – the Easy Medicines for Burden Reduction And Care Enhancement (EMBRACE) study** 14:00 - 14:00
Oral Presenter: Sarah Cameron, GB

P400 **Virtual appointments: a barrier to engagement or improving person-centred care?** 14:00 - 14:00
Oral Presenter: Lisa Morrison, GB

P401 **Video call fatigue - how do patients feel?** 14:00 - 14:00
Oral Presenter: Fiona Moore, GB

P402 **Initiating a home blood monitoring service for adults with cystic fibrosis** 14:00 - 14:00
Oral Presenter: Katie Baker-Wardle, GB

P403 **Hospital care at home: experiences of Ipswich Hospital's Multi-disciplinary (MDT) approach to holistic and individualised cystic fibrosis care** 14:00 - 14:00
Oral Presenter: Karen Richards, GB

P404 **Does knowledge of cystic fibrosis affect adherence to home monitoring? results from the CLIMB-CF study** 14:00 - 14:00
Oral Presenter: Claire Edmondson, GB

P405 **Adherence in the use of digital technology for home monitoring in patients with cystic fibrosis** 14:00 - 14:00
Oral Presenter: Daniela Savi, IT

Workshop
15:00 - 16:30 R1

***WS10* - WS10 - Changes in the clinical landscape in the era of CFTR modulators**

Chair: Silke van Koningsbruggen-Rietschel, DE
Chair: Lieven Dupont, BE

WS10.01 **The French Compassionate Programme of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del *CFTR* variant** 15:00 - 15:15
Oral Presenter: Pierre-Régis Burgel, FR

WS10.02 **Pharmacological effects of CFTR-modulation in cystic fibrosis patients after lung transplantation: interim results of the multicenter KOALA study** 15:15 - 15:30
Oral Presenter: Carina M E Hansen, NL

WS10.03 **Increasing cardiovascular risk in adults with cystic fibrosis related diabetes receiving CFTR modulator therapy (elexacaftor/tezacaftor/ivacaftor)** 15:30 - 15:45
Oral Presenter: Alex Chan, GB

WS10.04 **Analyzes of worldwide inhaled antibiotic prescriptions for *Pseudomonas. aeruginosa*** 15:45 - 16:00

Oral Presenter: Marianne S. Muhlebach, US

WS10.05 **Reduction of pulmonary exacerbations in people with cystic fibrosis in Germany between 2019 and 2022** 16:00 - 16:15
Oral Presenter: Susanne Naehrig, DE

WS10.06 **How representative are clinical trial cohorts of the general cystic fibrosis population? Implications for trial planning** 16:15 - 16:30
Oral Presenter: Rebecca Dobra, GB

Workshop
15:00 - 16:30 R2

***WS11* - WS11 - Rising to the challenge: navigating mental health and adherence in the era of CFTR modulators**

Chair: Edwina Landau, IL
Chair: Karoline Prinz, AT

WS11.01 **Challenging behaviours and mood changes in a large cohort of 6-11 year old children following elexacaftor/tezacaftor/ivacaftor initiation** 15:00 - 15:15
Oral Presenter: Tim Lee, GB

WS11.02 **Psychological wellbeing post-CFTR modulator therapy** 15:15 - 15:30
Oral Presenter: Helen Egan, GB

WS11.03 **Positive and negative impacts of elexacaftor/tezacaftor/ivacaftor: healthcare providers' observations across US Centres** 15:30 - 15:45
Oral Presenter: Alexandra Quittner, US

WS11.04 **Measuring barriers to adherence among people with cystic fibrosis starting treatment with elexacaftor/tezacaftor/ivacaftor: results from the RECOVER study** 15:45 - 16:00
Oral Presenter: Sharon Sutton, IE

WS11.05 **Medication burden among adults with cystic fibrosis prescribed CFTR Modulators: a cross-sectional survey** 16:00 - 16:15
Oral Presenter: Nicola J. Shaw, GB

WS11.06 **What to do when your patient "ghosts" you: an ethical framework for the new era of CFTR modulators** 16:15 - 16:30
Oral Presenter: Mark Chilvers, CA

Workshop
15:00 - 16:30 R3

***WS12* - WS12 - Nutrition: changes in practice**

Chair: Olaf Sommerburg, DE
Chair: Dee Shimmin, GB

WS12.01 **Early growth in Danish children with cystic fibrosis since 2000** 15:00 - 15:15
Oral Presenter: Karlen Bader-Larsen, DK

WS12.02 **Erythrocyte essential fatty acid status and its association** 15:15 - 15:30

	with breastfeeding, growth and early-onset lung disease in young children with cystic fibrosis *Oral Presenter*: HuiChuan Lai, US	
WS12.03	**Impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in children with cystic fibrosis** *Oral Presenter*: Laura Schembri, GB	15:30 - 15:45
WS12.04	**An "expanding area" of interest- the effect of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on body image and weight** *Oral Presenter*: Alice Darby, GB	15:45 - 16:00
WS12.05	**Is nutritional status still an important contributor to lung function in modern day cystic fibrosis?** *Oral Presenter*: Tamarah Katz, AU	16:00 - 16:15
WS12.06	**The changing landscape of tube feeding in the post modulator era** *Oral Presenter*: Liz May, GB	16:15 - 16:30

Workshop
15:00 - 16:30 R4

***WS13* - WS13 - Sampling and characterisation of the airway microbiome**

Chair: Valerie Waters, CA
Chair: Michael Tunney, GB

WS13.01	**The cystic fibrosis Home Sputum-Induction Trial (CF-HomeSpIT - ISRCTN86523335) to evaluate home sputum-induction and early morning saliva sampling in children with cystic fibrosis** *Oral Presenter*: Julian Forton, GB	15:00 - 15:15
WS13.02	**Comparison of qPCR and 16S rRNA marker-gene Next-Generation Sequencing (NGS) for the detection and quantification of respiratory pathogens in the sputum of people with cystic fibrosis (PwCF).** *Oral Presenter*: Gisli Einarsson, GB	15:15 - 15:30
WS13.03	**Microbiology of upper and lower airways of cystic fibrosis (CF) patients in stable conditions and in lung transplant patients** *Oral Presenter*: Daniela Dolce, IT	15:30 - 15:45
WS13.04	**Shotgun metagenomic for cystic fibrosis gut-lung microbiome and antibiotic resistant genes characterisation** *Oral Presenter*: Natalia Bastón-Paz, ES	15:45 - 16:00
WS13.05	**The short- and long-term effects of antibiotic treatment on the oropharyngeal and fecal microbiota in infants with cystic fibrosis** *Oral Presenter*: Lucas Hoffman, US	16:00 - 16:15
WS13.06	**Regional bronchoscopy sampling indicates that *Pseudomonas aeruginosa* infections persist throughout the lung after elexacaftor/tezacaftor/ivacaftor (ETI) due to intra-lung bacterial migration** *Oral Presenter*: Samantha L Durfey, US	16:15 - 16:30

Workshop
15:00 - 16:30 R5

***WS14* - WS14 - Airway epithelial homeostasis in CF: what and how to address it**

Chair: Nicoletta Pedemonte, IT
Chair: Shafagh Waters, AU

WS14.01	***Ex vivo* whole lung model of cystic fibrosis (CF) for therapeutic screening** *Oral Presenter*: Meghan Pinezich, US	15:00 - 15:15
WS14.02	**Cystic fibrosis personalised medicine; paediatric *in vitro* airway cell models to predict CFTR modulator patient outcomes** *Oral Presenter*: Laura K Fawcett, AU	15:15 - 15:30
WS14.03	**Combined therapeutic strategies for the restoration of airway epithelial integrity and function in cystic fibrosis** *Oral Presenter*: Emmanuelle Brochiero, CA	15:30 - 15:45
WS14.04	***Pseudomonas aeruginosa* infection drives complex host responses in a cystic fibrosis-derived airway model** *Oral Presenter*: Claudia A Colque, DK	15:45 - 16:00
WS14.05	**Effect of an agro-based compound (A-bC) on remodelling and regeneration of airway epithelium in cystic fibrosis** *Oral Presenter*: Damien Adam, CA	16:00 - 16:15
WS14.06	**Single cell RNA sequencing of lung biopsies reveals altered immune-structural cell crosstalk in cystic fibrosis** *Oral Presenter*: Ralph Stadhouders, NL	16:15 - 16:30

Workshop
17:00 - 18:30 R1

***WS15* - WS15 - Late Breaking Science**

Chair: Dorota Sands, PL
Chair: Marcus Mall, DE

WS15.01	**SP-101 gene therapy restores CFTR function in human CF airway epithelial cultures and drives hCFTRΔR transgene expression in the airways of CF and non-CF ferrets** *Oral Presenter*: Katherine Excoffon, US	17:00 - 17:14
WS15.02	**A phase 1b/2a randomized, double-blind, placebo-controlled, multicenter study evaluating nebulized phage therapy in cystic fibrosis subjects with chronic Pseudomonas aeruginosa pulmonary infection** *Oral Presenter*: Urania Rappo, US	17:14 - 17:28
WS15.03	**Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in people with cystic fibrosis (CF) and at least one F508del allele: an open-label, 192-week extension study** *Oral Presenter*: Deepika Polineni, US	17:28 - 17:42
WS15.04	**LONGITUDE: An observational study of the long-term effectiveness of ivacaftor/tezacaftor/elexacaftor in people with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry** *Oral Presenter*: Gabriela Vega-Hernandez, GB	17:42 - 17:56

WS15.05	**Effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) treatment on markers of inflammation in people with cystic fibrosis (CF)** *Oral Presenter*: Siobhan O´Brien, US	17:56 - 18:10
WS15.06	**Mutation class dependent signatures outweigh disease associated processes in cystic fibrosis cells** *Oral Presenter*: Lucia Santos, PT	18:10 - 18:30

Workshop
17:00 - 18:30 R2

***WS16* - WS16 - Clinical effectiveness of CFTR modulators: data from registries**

Chair: Jane Davies, GB
Chair: Andreas Jung, CH

WS16.01	**Highly-effective CFTR modulator therapy with elexacaftor/tezacaftor/ivacftor (ETI) leads to age-dependent changes of typical cystic fibrosis hallmark pathogens – data from the German cystic fibrosis registry** *Oral Presenter*: Anna-Maria Dittrich, DE	17:00 - 17:15
WS16.02	**Real-world (RW) clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in children with cystic fibrosis aged 6-11 years: interim results from the HELIO study** *Oral Presenter*: Lisa J. McGarry, US	17:15 - 17:30
WS16.03	**Registry-based study of people with cystic fibrosis (pwCF) treated with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA): Up to 2 years of real-world outcome data** *Oral Presenter*: Julie K. Bower, US	17:30 - 17:45
WS16.04	**Benefits of lumacaftor/ivacaftor (LUM/IVA) initiation in children with cystic fibrosis aged 2 through 5 years: Interim results from an ongoing registry-based study** *Oral Presenter*: Claire Kim, US	17:45 - 18:00
WS16.05	**Long-term impact of ivacaftor (IVA) in people with cystic fibrosis in Ireland** *Oral Presenter*: Barry Plant, IE	18:00 - 18:15
WS16.06	**International disparities in access to highly effective modulator therapies** *Oral Presenter*: Jonathan Guo, GB	18:15 - 18:30

Workshop
17:00 - 18:30 R3

***WS17* - WS17 - Strategies to replace or edit the genetic message in CF**

Chair: Anna Cereseto, IT
Chair: Garry Cutting, US

WS17.01	**Novel approaches based on sequence-specific RNA editing by ADARs to correct CFTR nonsense mutations causing cystic fibrosis** *Oral Presenter*: Viviana Barra, IT	17:00 - 17:15
WS17.02	**Improved adenine base editing approach to correct W1282X-CFTR**	17:15 - 17:30

Oral Presenter: Carlos M Farinha, PT

WS17.03	**An alternative mutation agnostic therapy for cystic fibrosis with oligonucleotide antisense** *Oral Presenter*: Christie Mitri, FR	17:30 - 17:45
WS17.04	**Developing a non-viral gene therapy strategy for treating lung cystic fibrosis disease** *Oral Presenter*: Bei Qiu, IE	17:45 - 18:00
WS17.05	**LUNAR ®-CF mRNA replacement therapy restores CFTR expression and function in human bronchial epithelial cells** *Oral Presenter*: Javier Campos-Gomez, US	18:00 - 18:15
WS17.06	**F/HN pseudotyped lentiviral vector-mediated transduction of non-human primates** *Oral Presenter*: Uta Griesenbach, GB	18:15 - 18:30

Workshop
17:00 - 18:30 R4

***WS18* - WS18 - Modifying inflammation in the CF airways**

Chair: Isabelle Fajac, FR
Chair: Hettie Janssens, NL

WS18.01	**Impact of elexacaftor/tezacaftor/ivacaftor therapy on sputum metabolomics in adult cystic fibrosis** *Oral Presenter*: Susan Kim, US	17:00 - 17:15
WS18.02	**ETI triple therapy shows sustained, progressive normalisation of airway cytokine and antiprotease balance and systemic inflammation over one year of treatment** *Oral Presenter*: Mark P Murphy, IE	17:15 - 17:30
WS18.03	**The effect of CFTR modulator therapy on the sputum proteome in cystic fibrosis** *Oral Presenter*: Rosie Maher, GB	17:30 - 17:45
WS18.04	**Change in markers of systemic inflammation after elexacaftor/tezacaftor/ivacaftor initiation: results from 18 months follow-up in the Danish cystic fibrosis cohort** *Oral Presenter*: Thomas Bryrup, DK	17:45 - 18:00
WS18.05	**Improved diagnosis of early aspergillus lung disease in cystic fibrosis (IDEAL) study design and first results** *Oral Presenter*: Federico Mollica, NL	18:00 - 18:15
WS18.06	**The impact of cytomegalovirus on airway epithelial gene expression** *Oral Presenter*: Julianna Svishchuk, CA	18:15 - 18:30

Workshop
17:00 - 18:30 R5

***WS19* - WS19 - Complex Psychosocial/Nursing case studies**

Chair: Katrien Van Gompel, BE
Chair: Espérie Burnet, FR

WS19.01	**Non-adherence in the twilight zone: the complexity of complex medications** *Oral Presenter*: Laura Moyens, BE	17:00 - 17:30
WS19.02	**"Could it be the new meds?" Clinical Psychology case study reminding us to ask all the old questions in this era of all new modulator medications** *Oral Presenter*: Helen Love, GB	17:30 - 18:00
WS19.03	**Triple therapy for Cystic Fibrosis (Elexacaftor/Tezacaftor/Ivacaftor): desensitization after an adverse reaction with severe skin rash** *Oral Presenter*: Juliana Roda, PT	18:00 - 18:30

Saturday, 10. June 2023

Symposium
09:00 - 10:30 R1

***S21* - Symposium 21 - Novel endpoints in clinical trials**

Chair: Damian Downey, GB
Chair: Philippe Reix, FR

PK studies in children – pitfalls and challenges 09:00 - 09:22
Speaker: Saskia De Wildt, NL

Airway clearance: can it be measured? 09:22 - 09:44
Speaker: Gemma Stanford, GB

Radiological endpoints in pre-school children 09:44 - 10:06
Speaker: Harm Tiddens, NL

Measuring bugs in the era of CFTR modulators 10:06 - 10:30
Speaker: Jerry Nick, US

Symposium
09:00 - 10:30 R2

***S22* - Symposium 22 - Inflammation in CF organs**

Chair: Olaf Eickmeier, DE
Chair: Dorota Sands, PL

Intrinsic CFTR related airway inflammation 09:00 - 09:22
Speaker: Robert Gray, GB

Pathogen induced airway inflammation 09:22 - 09:44
Speaker: Michael Tunney, GB

2023 Update on gut inflammation 09:44 - 10:06
Speaker: Jochen Mainz, DE

Inflammatory joint disease in cystic fibrosis 10:06 - 10:30
Speaker: Jobst Roehmel, DE

Symposium
09:00 - 10:30 R3

***S23* - Symposium 23 - CFTR-related pancreas disease**

Chair: Frank Bodewes, NL
Chair: Stephanie Van Biervliet, BE

Pancreatic complications in cystic fibrosis from bench to bedside 09:00 - 09:22
Speaker: Zachary Sellers, US

CFTR mutations in the pancreas 09:22 - 09:44
Speaker: Grzegorz Oracz, PL

The effect of CFTR modulators on exocrine pancreatic function 09:44 - 10:06
Speaker: Keith Chee Y. Ooi, AU

CFTR related disorders of the pancreas 10:06 - 10:30
Speaker: Isabelle Scheers, BE

Symposium
09:00 - 10:30 R4

***S24* - Symposium 24 - Understanding more about CFSPID: from diagnosis to outcomes and the role of registries**

Chair: Alexander Elbert, US
Chair: Maya Desai, GB

Newborn screening programmes and CFSPID epidemiology across Europe 09:00 - 09:18
Speaker: Carlo Castellani, IT

Phenotypes, care pathways and outcomes in CFSPID 09:18 - 09:36
Speaker: Anne Munck, FR

CFSPID should be included within national CF Registries (PRO) 09:36 - 09:58
Speaker: Susanna McColley, US

CFSPID should be included within national CF Registries (CON) 09:58 - 10:20
Speaker: Andreas Jung, CH

Discussion 10:20 - 10:30

Symposium
09:00 - 10:30 R5

***S25* - Symposium 25 - Exploiting novel targets for cystic fibrosis therapies**

Chair: Miquéias Lopes-Pacheco, PT
Chair: Iwona Pranke, FR

Targeting SMG6-mediated pathway to rescue nonsense CFTR variants 09:00 - 09:22
Speaker: Lulu Huang, US

Global functional genomics reveals GRK5 as a therapeutic target for cystic fibrosis 09:22 - 09:44
Speaker: Hugo Botelho, PT

Esc peptides: novel therapeutic agents with dual potentiator and antimicrobial activity 09:44 - 10:06
Speaker: Maria Luisa Mangoni, IT

Potassium channels as alternative targets to modulate transepithelial fluid secretion 10:06 - 10:29
Speaker: Guy Moss, GB

Closing Plenary
11:00 - 12:30 R1

Closing Plenary

“Hurdles” on genetic therapies - Delivery, other organs.. 11:00 - 11:30
Speaker: Patrick Harrison, IE

Longitudinal data from the ECFS-Patient Registry: What happened in the last decade and what can we learn from it about the future? 11:30 - 12:00
Speaker: Eitan Kerem, IL

Closing Ceremony
12:30 - 12:50 R1

Closing Ceremony